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ABSTRACT 
Title: Study of drug induced-skin reactions in the patients attending 
outpatient department of dermatology 
Degree for which submitted :  Doctor of Medicine (M.D) in 
Pharmacology. 
Supervisor & Guide :  Prof. Dr. C. Ramachandra Bhat, M.D.,  
Department :  Department of Pharmacology and 
Dermatology.  
College                                  :  Kilpauk Medical College, Chennai.  
University :  The Tamilnadu Dr.MGR Medical 
University, Chennai. 
Year :  2011 -2015. 
   Adverse drug reaction is any noxious change which is suspected to be 
due to drug, occurs at doses normally used in humans for prophylaxis, 
diagnosis, therapy of disease or for modification of physiological function. 
Adverse drug reactions cause both morbidity and mortality. Drug induced skin 
reactions are the most common type of adverse drug reaction and clinical 
presentation varies. We investigated the profile of drug induced skin reactions 
in the patients attending outpatient department of Dermatology, Kilpauk 
Medical College and Hospital, from September 2011 to February 2013. Data 
were recorded in WHO Suspected adverse reaction report form and analyzed 
statistically by Chi-square test. Causality and severity of adverse drug reaction 
were done.  In conclusion, analyzing 100 ADRs men were more affected than 
female. Drug rash was the most common drug induced skin reaction. The 
suspected drug causing more reactions was Antibacterial agent. Hence ADR 
data base studies conducted across multiple centres provide early warning 
signals in preventing adverse drug reactions. 
 Keywords : ADR, WHO, CAUSALITY. 
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ABBREVIATIONS 
ADR           -     Adverse drug reaction 
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IL               -       Interleukin 
NSAID      -        Non-steroidal anti inflammatory drugs 
FDA         -      Food and drug administration 
CIOMS       -         Council for international organization of medical sciences 
ICH           -      International conference on harmonization 
SUSAR      -   Suspected unexpected serious adverse reaction 
SSAR        -      Suspected serious adverse reaction 
Cyp           -      Cytochrome 
MDR         -          Multidrug resistant 
Pgp             -          P glycoprotein 
ACE           -          Angiotensin converting enzyme 
ARB           -          Angiotensin receptor blocker 
HLA           -          Human leucoyte antigen 
Ig                -          Immunoglobulin 
LD               -         Lethal dose 
PSUR          -         Periodic safety update report 
PMS            -         Post marketing surveillance 
GCP             -        Good clinical practice 
ATN           -          Acute tubular necrosis 
PPI              -         Proton pump inhibitors 
RAST          -         Radio allergen absorbent skin test 
EM               -         Erythema multiforme 
SJS               -         Steven Johnson syndrome 
HIV               -        Human immunodefiency virus 
G-CSF           -        Granulocyte colony stimulating factor 
OTC               -        Over the counter 
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INTRODUCTION 
The art of medicine is defined as a fine art of practice combining 
medical knowledge, intuition, and judgment in the care of patients.1 The major 
tool of medicine is drug prescribed. A drug is an active chemical molecule used 
for diagnosis, prevention, and treatment of a disease.2 These drugs which are 
prescribed for medical illness can also produce adverse effects which are 
manifested differently according to the system involved. 
An  Adverse drug Reaction is defined as ‘Any  noxious change which is 
suspected to be due to a drug, occurs at doses normally used in humans,  for 
prophylaxis, diagnosis and therapy of disease or for modification of 
physiological function (WHO definition).3 It excludes therapeutic failure, 
overdose, drug abuse, non compliance and medication errors. 
            Adverse drug reactions cause death in 0.1% of medical and 0.01 % of 
surgical patients. Although only few patients are affected, ADRs adversely 
affect the quality of life. 
       The morbidity and mortality associated with adverse effects of drugs often 
present as diagnostic problems because they involve every organ and system of 
the body. They are mistaken for signs of underlying disease, resulting in 
unnecessary investigations and delay in treatment. Moreover treatment of 
ADRs increases the costs of patient care. 
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           Cutaneous drug eruptions are the most common type of adverse 
reactions to drug therapy, with an incidence rate of 2–6% .4 Any medicine can 
induce skin reaction.  Non-steroidal anti-inflammatory drugs (NSAIDs), 
antibiotics and antiepileptics, have drug eruption rates approaching 1–5%.5  
             The clinical presentation of drug related cutaneous eruption ranges 
from mild rash to severe rash besides causing life-threatening reactions. 
Serious reactions include angio-oedema, erythroderma, Stevens–Johnson 
syndrome and toxic epidermal necrolysis. Sometimes drug eruptions occur as 
part of a multiorgan involvement like drug-induced systemic lupus 
erythematosus.    
           Cutaneous drug reaction is suspected in any patient who is currently 
taking any medicine or recently been exposed to any medicine including the 
prescribed and over-the-counter medicines, herbal or homoeopathic 
preparations, vaccines or contrast media. In some patients non-drug 
components of a medicine, i.e. the pharmaceutical excipients may also cause 
hypersensitivity reactions like cutaneous drug eruptions. 
                Hence, this study was done to analyze the profile of drug induced-
skin reactions caused by different drugs including the type and severity of drug 
induced skin reactions. 
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REVIEW OF LITERATURE 
HISTORY      
A drug causes good as well as harmful effects. Public and Professional 
concerns about harmful effects of drug started in late 19th century. Committees 
and commissions were started in 1870 to 1890 to investigate sudden death due 
to chloroform anesthesia which later was found due the effect of chloroform 
sensitizing the myocardium to arrythmogenic effects of catecholamines.6 In 
USA in 1937, 107 people died due to an elixir of sulfanilamide that contained 
solvent diethylene glycol, which led to the establishment of Food and Drug 
administration to impose quality criteria for drug manufacturing. 
            In 1961, Thalidomide disaster occurred in which 6000 -250000 
offsprings  were born with phocomelia .The incident was found to occur due to 
drug thalidomide which is a hypnotic  taken by pregnant women in first 
trimester for morning sickness. 7, 8 The thalidomide incident led public outcry to 
all the institutions around the world of drug regulatory authorities to make 
necessary sophisticated approaches for preclinical testing and clinical 
evaluation of drugs before marketing, increased awareness of adverse effects of 
drugs and methods of detecting them. Hence in1968 International drug safety 
monitoring by WHO came as a collaborative effort by 10 countries. 
         The adverse reactions to widely prescribed drugs have serious impact on 
the society. Hence knowledge and efficient reporting forms the basis of 
Pharmacovigilance. The national Pharmacovigilance centres were established 
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after 1972 that work in collaboration with WHO collaborating centre for 
international drug monitoring in Uppsala, Sweden (The Uppsala Monitoring 
Centre). 
           The new legislations and qualitative requirements have led to the 
establishment of Council for International Organizations of Medical sciences 
(CIOMS) and International Conference on Harmonization (ICH) which is 
instrumental in the development of Pharmacovigilance worldwide. 
          In India drug safety monitoring was proposed in 1986. Adverse reaction 
monitoring system of 1986 consisted of 12 regional centres. In 1997   more 
efforts began, in cooperation with WHO Uppsala monitoring centre. 
             On 1st January 2005, the more ambitious National Pharmacovigilance 
Programme of India was launched with WHO support and World Bank 
funding. The implementation of Schedule Y has also added support to National 
pharmacovigilance, so that it is mandatory to report all adverse events 
including suspected unexpected serious adverse reactions from clinical trials. 
       Hence adverse drug reactions to widely prescribed drugs have serious 
impact on the society which has to be researched. 
EPIDEMIOLOGY 
10-20 % of patients admitted in the hospital suffer from an adverse drug 
reaction. In the  hospital 0.24-2.9 % deaths are due to adverse drug reaction.9 2-
6% of hospital admissions are due to adverse drug reaction.10-12 In England  a 
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study was conducted which showed that more than 40 % of patients undergoing 
drug therapy are upset by their treatment13 due to drug reaction.  
Cutaneous drug eruptions are the most common type of ADR with 
incidence of about 2-5%. 75% to 95 % of cutaneous drug eruption are 
maculopapular rash/drug rash followed by   utricaria.14  20% of emergency 
room visits for adverse event are due to antibiotics and nonsteroidal anti-
inflammatory drugs   which causes reaction of about 1 in 2000.15.The reaction 
rate for digoxin, lidocaine, prednisolone, codeine are less than 1 in 1000. 
ADR RISK FACTORS 
Age (children and elderly), gender, multiple medications, multiple co- 
morbid conditions, inappropriate medications that were prescribed and used, 
improper  monitoring, end-organ dysfunction, altered physiology, prior history 
of ADR’s, extent (dose) and duration of exposure, genetic predisposition are 
the various risk factors. 
        Adverse drug reactions are more common in elderly due to changed 
pharmacokinetics and pharmacodynamics through organ failure, concomitant 
disease and drug interactions. 
CLASSIFICATION OF ADVERSE DRUG REACTION  
Adverse drug reaction is classified into many types according to dose, 
severity, type of effect, time, frequency and causality. 
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A) Classification based on dose relationship 16  
1) Dose related:     a) Pharmaceutical variation b) Pharmacokinetic 
variation –Pharmacogenetic variation, hepatic disease, renal disease, 
cardiac disease, thyroid disease, drug interactions. c) Pharmacodynamic 
variation - Hepatic disease, altered fluid and electrolyte balance, drug 
interactions. 
2) Non-dose-related:   a) Immunological reactions  
b) Pseudoallergic reactions    c) Pharmacogenetic variation. 
3) Long term effects:  a) Adaptive changes  
b) Rebound phenomenon  c) Other long term effects.                                               
4) Delayed effects:         a) Carcinogenesis  
b) Effects concerned with reproduction-1) Impaired fertility  
2) Teratogenesis - Adverse effects on the fetus during early pregnancy, 
late pregnancy 3) Adverse effects due to drugs in breast milk 
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B) Classification according to type of effects (Pharmacological 
classification17) 
  
S.No Type Type of effect Definitions Examples 
1. A Augmented Adverse effects that are 
known to occur from the 
pharmacology of drug and 
dose related .They are 
seldom fatal and are 
relatively common.  
Hypoglycemia due to 
insulin injection, 
bradycardia due to Beta 
adreneoreceptor 
antagonists, hemorrhage 
due to anticoagulants 
2. B Bizarre 
effects 
Adverse effects that occur 
unpredictably and often 
have a high rate of 
morbidity. They are 
uncommon 
Anaphylaxis due to 
penicillin, Acute hepatic 
necrosis due to halothane, 
bone marrow suppression 
by chloramphenicol. 
3. C Chronic 
effects 
Adverse effects that occur 
only during prolonged 
treatment and not with 
single dose. 
Iatrogenic Cushing’s 
syndrome with 
prednisolone, myofacial 
dystonia due to 
phenothiazines, colonic 
dysfunction with laxatives  
4. D Delayed 
effects 
Adverse effects that occur 
remote from treatment 
either in the children of 
treated patients or in 
patients themselves years 
after treatment. 
Secondary cancers in 
patients treated with 
alkylating agents for 
Hodgkin’s disease, 
craniofacial malformation 
in infants whose mothers 
have taken isotretinoin, 
clear cell carcinoma of 
vagina of female offspring 
of women who had 
diethylstilbestrol. 
5 E    End of 
treatment 
effects 
Adverse effects that occur 
when a drug is stopped 
especially when it is 
stopped 
suddenly(withdrawal 
effects) 
Unstable angina after Beta 
adrenoreceptor  antagonists 
are  stopped suddenly, 
Adrenocortical 
insufficiency with 
glucocorticoids, 
withdrawal seizures with 
anticonvulsants. 
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C) Classification according to the severity18  
1) Mild - Bothersome but requires no change in therapy. 
2) Moderate-Requires change in therapy, additional treatment, hospitalization. 
Definite     biochemical or structural changes occurs due to moderate 
involvement of vital organs.    
3) Severe - Potentially life threatening, causing permanent damage. Definitely 
requiring hospitalization due to severe impairment of vital organs. 
 D) Classification according to Seriousness 19 
            1) Suspected Unexpected Serious Adverse Reaction (SUSAR)  
            2) Suspected Serious Adverse Reaction (SSAR) 
 Both results in death, life threatening situations and require intervention to 
prevent permanent damage.  Both may result in disability and also causes 
congenital anomalies. 
E) Frequency classification 
         Report from CIOMS (Centre for international organization of medical 
sciences) working group III, Geneva 1995 20   
     1) Very common (Optional)    : >10% 
     2) Common (Frequent)             :  >1% and ≤ 10% 
     3) Uncommon (Infrequent)       :  >0.1% and ≤ 1% 
     4) Rare                                       :   0.01% and ≤ 0.1% 
     5) Very rare (Optional)                : <0.01% 
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F) Reaction time classification 
        Reaction time is defined as the time between the last drug exposure and 
the appearance of the first symptoms.21 
1) Acute                  :    0-60 Minutes (4.3 % of reactions) 
2) Subacute             :    1-24 Hours (86 % of reactions) 
3) Chronic               :    day to several weeks (3.5% of reactions) 
F)  WHO Causality classification 22  
Term Discription 
Certain  Event or laboratory test abnormality, with plausible time 
relationship to drug intake 
 Cannot be explained by disease or other drugs 
 Response to withdrawal plausible(pharmacologically, 
pathologically) 
 Event definitive pharmacologically or phenomenological(i.e. 
an objective and specific medical disorder or a recognized 
pharmacological phenomenon) 
 Rechallenge satisfactory, if necessary  
Probable/Likely  Event or laboratory test abnormality, with reasonable  time 
relationship to drug intake 
 Unlikely  to be attributed to disease or other drugs  
 Response to withdrawal clinically reasonable 
 Rechallenge not required  
Possible  Event or laboratory test abnormality ,with reasonable  time 
relationship to drug intake 
 Could not be explained by the disease or other drugs  
 Information on drug withdrawal may be lacking or unclear  
Unlikely  Event or Laboratory test abnormality with a time to drug 
intake that makes a relationship improbable(but not 
impossible) 
 Disease or other drugs provide plausible explanations 
Conditional/ 
Unclassified 
 Event or Laboratory abnormality 
 More data for proper assessment needed, or  
 Additional data under examination 
Unassessable / 
Unclassifiable 
 Report suggesting an adverse reaction  
 Cannot be judged because information is insufficient or 
contradictory 
 Data cannot be supplemented or verified 
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MECHANISM OF ADVERSE DRUG REACTION 
PHARMACEUTICAL VARIATION 
         Alteration in the drug quantity for systemic absorption or release of drug 
produces toxicity due to the influence of various factors, i.e., size of the particle 
in pharmaceutical preparation like tablet, capsule, injection, nature and quantity 
of excipients, materials used for coating. When an irritant drug come into 
prolonged contact with a small area of gastrointestinal tract it leads to gastric 
hemorrhage, ulceration and perforation e.g. potassium chloride tablets.23 
PHARMACOKINETIC VARIATIONS 
            Alteration in absorption, distribution, metabolism and excretion of drug 
causes adverse reactions. 
Absorption 
           It is the movement of unchanged drug from the site of administration to 
systemic circulation. The rate and extent of drug absorption affects the 
pharmacologic effect. Gastrointestinal intestinal system is mainly involved in 
absorption .Any motility changes alters absorption. 
Distribution 
         The transfer of drug between blood and extravascular fluids and tissue is 
distribution. The factors which affect the extravascular distribution are 
physiochemical characteristics, blood flow to the region, tissue binding, 
binding to plasma protein and  active transport. 
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          Binding of drugs to the tissues gains wider importance in causing 
adverse reaction. Some examples of ADRs due to extravascular tissue binding 
are as follows:    
1. Hepatotoxicity due to epoxides of halogenated hydrocarbons and 
paracetamol.24  
2. Renal toxicity by metallothionins  binding to heavy metals. 
3.  Interaction of melanin in skin with chloroquine and phenothiazines. 
4.  Yellow discoloration of teeth and bones due tetracycline in children. 
5.  Binding to DNA by cyclophosphamide, azathioprine leading to 
carcinogenesis. 
 Metabolism  
          The conversion of drug from one form to another is metabolism. 
Biotransformation is synonymous with metabolism. Organs involved are liver, 
gut, skin, lung, kidney, adrenals and placenta. 
         Liver is the major organ of metabolism. In the liver oxidation by 
Cytochrome P-450 group of isoenzymes plays an important role. Metabolism 
of oral anticoagulants, phenothiazines, tricyclic antidepressants, 
benzodiazepines, barbiturates, and isoniazid involves this route. 
Different races shows differences   in the metabolism. Acetylation of 
isoniazid is an example of Polymorphism. Slow acetylators presented with 
hepatotoxicity   and fast acetylators presented with peripheral neuropathy as 
adverse effect. Another example is Warfarin. Genetic variation in the 
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metabolism of warfarin by CYP2C9 is seen which leads to hemorrhagic 
incidence of 8-26 per 100 patient years.25               
                  The hepatic metabolism is reduced in any pathological condition 
like hepatitis, cirrhosis, obstructive jaundice and hepatic carcinoma. The blood 
flow to liver is reduced in congestive cardiac failure and Myocardial infarction 
which impairs the metabolism of drug like propanalol and lidocaine.     
            In renal diseases glycine conjugation of salicylates, vitamin D 
oxidation, procaine hydrolysis is affected. Glucuronidation is reduced in 
diabetes mellitus due low availability of Uridine diphospho glucuronic acid. 
Elimination or excretion  
          The drug or metabolite is transferred irreversibly to external environment 
which leads to termination of action of the drug. Kidneys are the prime organs 
of excretion. Also bile, sweat, breast milk, lungs play minor role. Reduced 
elimination leads to toxic reaction. Nephrotoxic drugs are used with caution in 
renal impairment. 
Drug interaction 
           Polytherapy leads to adverse drug reaction due drug interactions.26 An 
Australian study showed that 4.4% of all adverse drug reactions resulting in 
hospital admission were due drug interactions.27 The effect on metabolic 
pathway by drug interaction is due enzyme interaction or by enzyme 
inhibition.28 Increased metabolism and drug clearance occurs due to enzyme 
induction which does not cause adverse drug reaction. On the other hand 
enzyme inhibition leads to decreased drug clearance leading to toxicity. 
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Examples:       
1)  Interaction between CYP3A4 inhibitors Ketoconazole and erythromycin 
and terfenadine. 
2)  P-Glycoprotein (Pgp) over expression leads to resistance of antitumor 
drugs. P-Glycoprotein is encoded by MDR1 gene. 
3)  Digoxin toxicity with quinidine, amiodarone due inhibition of Pgp.29 
PHARMACODYNAMIC VARIATIONS 
In general population pharmacodynamic variability is compounded by 
diseases of various systems. Hepatic diseases alter pharmacodynamic 
parameters leading to hemorrhage or peptic ulcer with Non-steroidal anti 
inflammatory drugs. Hepatic encephalopathy causes brain sensitization to 
sedatives leading to frank coma. Sodium and water retention occurs with drugs 
like NSAIDs, carbamazepine, carbenoxolone, and sodium salt of penicillin. 
Bronchoconstriction in obstructive airway disease occurs when beta 
blockers are used.  Aminoglycoside precipitates neuromuscular blockade in 
Myasthenia gravis. Hypokalemia precipitates arrhythmia with antiarrythmics 
such as quinidine, procainamide, and dysopyramide causing Torsade de 
pointes.   Skeletal muscle relaxant – Tubocurarine’s action is prolonged by 
Hypocalcaemia. Hypotensive effect of ACE inhibitors is enhanced by fluid 
depletion. 
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IMMUNOLOGICAL / ALLERGIC / HYPERSENSITIVITY 
REACTIONS 
                   The drug and the patient are main factors in drug allergy. 
       Drug 
                Proteins, polypeptides, dextrans are immunogenic in nature. Haptens 
are smaller molecules that combine with body proteins and form antigens. 
Drugs or their metabolites act as haptens in immunological reactions. 
      Patient 
            Genetic factors play role in allergic reaction. In Atopic disease, eczema, 
asthma, hay fever, hereditary angioedema allergic reactions are more common. 
      HLA status    
               Human lymphocyte antigens are important for the function of  
T lymphocyte in stimulation by foreign antigens. HLA antigens are located on 
the short arm of chromosome 6. Nephrotoxicity due to pencillamine is 
increased in patients with HLA type B8 and DR3. Hydralazine associated 
Lupus like syndrome is seen in patients with HLA DR4.  
TYPES OF HYPERSENSITIVITY REACTIONS (Stephen MBD et al, 
1998) 
Type 1 reaction (Anaphylaxis/Immediate hypersensitivity)  
          Reaction occurs when the drug or metabolite combines with antigen 
specific Ig E on mast cells and basophils leading to the formation of 
drug/antigen-specific IgE cross-links. Hence chemical mediators like 
histamine, kinins, 5-hydroxy tryptamines and leukotrienes are immediately 
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released. This leads to clinical features like pruritus, urticaria, angio-oedema, 
bronchoconstriction and anaphylaxis. Aspirin, opioids, penicillins, radio-
opaque iodide containing contrast media and some vaccines commonly causes 
this type of reaction. 
 
Type II Reaction (cytotoxic reaction)  
                   IgG or an IgM-mediated mechanism plays a role. A Drug acts as 
hapten. The binding of antibody to cells with subsequent binding of 
complement leads to cell rupture with immediate release of chemokines. Due to 
this mechanism haemolytic anemia is caused by drugs like penicillins, 
cephalosporins, quinine and quinidine. Thrombocytopenia occurs with 
quinidine, digitoxin, and rifampicin. Drugs like phenylbutazone, 
chlorpropamide causes neutropenia. 
Type III reaction (Immune complex reaction)     
         They are mediated by intravascular immune complexes. Arises when both 
drug as antigen and antibodies like IgG or IgM class are present in the 
circulation and the antigen present in excess. The immune complexes are 
slowly removed by the phagocytes leading to their deposition in the skin and 
the microcirculation of joints, kidney, and gastrointestinal system manifested as 
fever, arthritis, maculopapular rashes and urticaria. Examples of type III 
reactions are Serum sickness, vasculitis and acute interstitial nephritis. Drugs 
like penicillin, streptomycin, sulfonamides, NSAIDs causes this type of 
reaction. 
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Type IV reaction (Cell-mediated or delayed Hypersensitivity reaction)                   
          Hapten- Protein complex sensitizes T Lymphocytes which causes 
inflammatory response. Examples include contact dermatitis or delayed skin 
tests to tuberculin. Contact dermatitis is caused by local anesthetic creams and 
topical antibiotics. Stevens–Johnson syndrome and toxic epidermal necrolysis 
(TEN) are Drug related delayed type hypersensitivity reactions which are 
serious in nature. 
Pseudoallergic reaction 
            Pseudoallergic reactions mimic Type 1 allergic hypersensitivity 
reaction. Severe reactions are called as anaphylaxis. Such reactions occur after 
exposure to any drug or radio contrast dye. Certain individuals like asthmatics 
are more prone to this type of reaction with aspirin. 
ADAPTIVE CHANGES   
             Drug therapy causes adaptive changes which form basis for some 
adverse reactions. Tardive dyskinesis with long term neuroleptic therapy for 
schizophrenia is one such adaptive response. Sudden withdrawal of long term 
drugs leads to rebound reaction as adverse effects. Barbiturate causes 
restlessness, confusion, convulsions when withdrawn suddenly. Syndrome of 
acute adrenal insufficiency is seen with withdrawal of long term Corticosteroid 
therapy. 
DELAYED EFFECTS 
          Carcinogenesis by drugs has been identified due to mechanisms like 
hormonal, gene toxicity and immune suppression. 
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Hormonal Mechanism 
      Increased risk of breast cancer is seen in women taking Hormone 
replacement therapy for more than 5 years and the risk is 50 %. Carcinoma of 
uterus risk is increased with tamoxifen treatment for breast carcinoma. 
Gene toxicity 
           This is a Mystery. Examples include: 
1) Bladder cancer risk increased with cyclophosphamide which is 
prevented by using Mesna. 
2) Phenacetin abuse leading to carcinomas of renal pelvis 
3) Non-lymphocytic leukemia with alkylating agents like melphalan, 
cyclophosphamide and chlorambucil. 
 
Suppression of immune response 
                   Increased risk of is seen with immunosuppressive drugs like 
azathioprine after renal transplant. Cancers of liver, biliary tree, soft tissue 
sarcomas   and squamous cell carcinoma are increased in patients taking 
immunosupressives. 
REPRODUCTIVE EFFECTS 
A) Fertility impairment     
             Cytotoxic drugs cause female infertility through ovarian failure. 
Reversible male fertility impairment due reduced spermatozoa production was 
caused by sulphasalazine, nitrofurantoin, and Monoamine oxidase inhibitors. 
Azoospermia leading to permanent impairment was caused by alkylating 
agents like cyclophosphamide and chlorambucil. 
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B) Teratogenesis            
            When a drug is consumed during any trimester of pregnancy 
developmental anomalies occurs in the fetus. This is called as teratogenesis.  
             Drugs like phenytoin, carbamazepine and lithium are teratogenic in 
nature. 
C) Drugs in breast milk     
              Drugs excreted in the breast milk affect fetus. 
CLINICAL TRIALS AND DRUG DEVELOPMENT 
         A drug identified first as lead compound has to undergo preclinical 
testing in animals and clinical trials in humans which consists of four phases 
before marketing.  
Preclinical toxicity study 
The Objectives of Preclinical toxicity studies include: 1) Identifying all 
potential human toxicities 2) Tests designed to define the mechanisms of 
toxicities and 3) Predicting the specific and relevant toxicities that is to be 
monitored in clinical trials.30 Following are the different types of acute toxicity 
study methods: 
1) Acute toxicity    
This study is done to identify single large dose that is lethal in 
approximately 50% of animals and that is the maximum tolerated dose. Tested 
with two species, two routes, single dose.31 
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2) Subacute toxicity 
               This study is done to identify the target organs of toxicity by using 
three doses, two species which takes   4 weeks to 3months time. If the clinical 
use is for a longer period then the time taken for the study is also longer. The 
parameters used are clinical chemistry, physiologic signs, autopsy studies, 
hematology, histology and electron microscopy studies.30  
3) Chronic toxicity  
            Similar to subacute study. Here Rodent and non-rodent species are used 
for   6 months or more. Sometimes goes hand in hand with clinical trials with 
controls plus three doses. 
 The effect on reproductive performance, mating behavior, reproduction, 
parturition, progeny, birth defects, teratology, perinatal, lactation and post natal 
changes are studied. It is done simultaneously with clinical trials in drug 
development.31 
4) Carcinogenic potential 
                   The study is done for two years in two species so that the drug is 
used in humans for prolonged periods.  Histology, hematology and autopsy 
results are studied.  Rarely transgenic mice for shorter periods as single species 
is used. 
5)   Mutagenic potential 
           The changes on genetic stability, mutations in bacteria (Ames test), and 
mammalian cells in culture are identified. It  determines clastogenicity in mice 
so as to find the mechanisms of actions of toxicities. Genes and  proteins 
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pathways involved are discovered.It  helps to identify safer drugs with new 
assessment toxicity designs. 
           Several quantitative estimates like “no-effect” dose—the maximum 
dose at which a specified toxic effect is not seen; the” minimum lethal 
dose”—the smallest dose that is observed to kill any animal; and, the” median 
lethal dose” (LD50)—the dose that kills approximately 50% of the animals   
are studied.30 LD50 is estimated from a small group of   animals. 
 Limitations of preclinical testing   
1. Time-consuming and expensive.  The total cost of preclinical studies 
was estimated around 41 million per successful drug. 2 to 5 years 
required to collect and analyze data. 
2.  Animals are needed in large numbers to get valid data. In vitro methods 
like cell culture and tissue culture are used as alternatives but are having 
limited value. Animal welfare interested public are  opposing animal 
testing. 
       3.   Toxicity data extrapolation from animals to humans is not reliable 
completely. 
       4.   Detection of rare adverse effects is not possible. 
CLINICAL TRIAL 
          Clinical trial means a systematic study of a new drug in human subjects 
to generate data for discovering or verifying the clinical claims or 
pharmacological and adverse effects with an aim to determine the safety and 
efficacy of the drug in question.32 The investigational new drug application has 
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to be sent to Drug Controller General, Govt. of India, New Delhi before 
starting trials in humans with all the details of animal studies to get approval. 
The study started after getting written informed consent from the volunteers. 
         The clinical trials are conducted in four phases as phase 1, phase 2, 
phase3 and phase 4.33 
PHASE 1 
       Small number of about 25-100 healthy volunteers are used. To study a 
drug for a disease the concerned patients with particular disease are used. 
Safety, tolerability, safe clinical dosage range, pharmacokinetic parameters 
identification and predictable toxicity are assessed. 
PHASE 2 
             About 200 to 400 patients with target disease are used as volunteers. 
Efficacy, therapeutic benefits and side effects are studied. 
PHASE 3 
        Large scale multicenteric trials in 1000 to 5000 plus patients are 
conducted to establish safety and efficacy so that errors in phase I and phase 2 
trials are minimized. After this New Drug application is filed to Drug Control 
Authorities. 
PHASE 4 
        This is a post marketing field trial so as to identify rare side effects, 
unknown interactions, and new uses. 5000 or more number of subjects are  
used. The manufacturer has to submit Periodic Safety Update Report (PSUR) 
once in six months in first 2 years and then once in a year for 2 years. 
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Limitations of clinical trial 
     Time limit, Size or number of patients, Non Representative patient 
selection, children and pregnant women exclusion, limited indications, limited 
concomitant medications usage and more compliant patients in clinical trials 
are limiting factors.  
 POST MARKETING SURVEILLANCE  
             Despite of meticulous monitoring in clinical trial some  adverse effects 
are missed due to the limitations. High incidence ADRs are only identified in 
clinical trials. Unseen adverse effects occur when a drug is released into the 
market for use.34 Hence it became mandatory to do Post marketing 
surveillance. Post Marketing Surveillance (PMS) is a term used to describe the 
research and studies associated with product safety evaluation after a drug has 
been approved for marketing.35 The activities include collection, reporting and 
analyzing data. Thus new safety informations are collected. 
Methods of Post Marketing Surveillance 
         The methods include Spontaneous reporting system, Case study, case 
control studies, Cohort study, Randomized trials, Database research with 
monitoring and Meta analyses. 
Spontaneous reporting system  
          A spontaneous report is an unsolicited communication by healthcare 
professionals or consumers to a company, regulatory authority or other 
Organization like WHO-regional center, poison control centre that describes 
one or more adverse drug reactions in a patient who was given one or more 
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medicinal product that does not derive from a study or any organanized data 
collection scheme.36  
         The possible relationship between a drug and an adverse event, the 
relationship being unknown or incompletely documented previously is known 
as Signal.37 Signal detection is more important and  is needed for signal 
generation. Many countries have their own pharmacovigilance system. 
France 
             French pharmacovigilance system has a network of 31 regional centers 
located in teaching hospitals, coordinated with the French Medicines Agency 
(“Agence Francoise de Securite Sanitaire des Produits de Sante”-
AFSSAPS).The databases of French pharmacovigilance system was studied 
from 1986 to 2001 which showed that report of   all drugs and ADRs showing 
increased reporting overtime by specialist and more for anti-infective drugs.38 
WHO INTERNATIONAL SYSTEM                                                                                        
              The WHO member states are involved in monitoring and reporting. 
More  than 3.7 million cases are reported. WHO programme was established 
in1968 with centre for drug monitoring in Uppsala in Sweden. 
Functions of Uppsala Monitoring Centre 
1)  New adverse drug reaction identified and analyzed  as signals from case 
report information and submitting to National centres and then to WHO 
database. At UMC a data mining approach is used. 
 24
2)  WHO database is used as reference signal for signal strengthening and 
web based search facilities are available. 
3)  ‘Vigimed’ is an e-mail information exchange system which exchanges 
information between national centres and WHO. 
4)  Periodical Newsletters, guidelines, books are published. 
5)  Supply of tools like WHO Drug Dictionary and WHO Adverse Reaction 
Terminology for management. 
6)  Training and consultancy support to National centres. 
7) “Vigiflow” is the Computer Software for case reporting which is 
designed to support national centres for case reporting. 
8)  Conducting annual meeting to discuss scientific and organizational 
matters. 
9)  Scientific development of Pharmacovigilance by Methodical research. 
 
US FDA “MedWatch” 
         MedWatch is the Safety information and adverse event reporting system 
of US FDA. It gives timely clinical knowledge and safety issues of medicinal 
products both prescribed as well as over-the-counter drugs, medical and 
radiation-emitting devices and nutritional products like infant formulas and 
dietary supplements. Reporting can be done by practitioner on phone, on line, 
by MedWatch form submission, or by fax. The risk versus benefit is taken into 
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consideration and if risk is more then FDA can advise for withdrawal of drug 
from market. 
UK ‘YELLOW CARD’ System  
          In UK the spontaneous reporting is Yellow Card scheme. Any suspected 
reaction has to be reported by the Medical and dental profession members and 
all reports are kept confidential. The following Adverse effects are reported. 
1)  Halothane induced Jaundice 39  
2)  Estrogens and thromboembolism40 
3)  Metochlopropamide and Extra pyramidal side effects 
4)  Piroxicam induced Congestive cardiac failure 
5)  Amiodarone induced Hepatitis. 
NATIONAL PHARMACOVIGILANCE SYSTEM OF INDIA41                   
           National Pharmacovigilance programme was launched in India by the 
Central Drugs Standard Control Organization, Ministry of Health and Family 
welfare in November 2004. 
The aim is to generate the culture of ADR notification by health care workers 
like doctors, dentists, pharmacists, nurses. The data is sent in chain like manner 
from peripheral  pharmacovigilance centre to regional centre, from regional 
centre  to zonal centre, from zonal  to National Centre and then finally  to 
WHO- UMC. 
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Limitations of spontaneous reporting system  
            No direct information, under reporting, inferior quality of information, 
many influencing factors, and reporters capacity to identify a reaction weakens 
the spontaneous reporting system. 
CASE REPORTS 
       Previously unidentified adverse effect of drugs come to light by individual 
case reports. Anorexant drug fenfluramine after using 20 years for weight 
reduction was found to have associated with valvular heart disease and 
pulmonary hypertension and was withdrawn.42 
CASE CONTROL STUDIES 
          Comparitive analytical retrospective study was conducted so as to 
identify cases of diseases or events. Controls are selected from general 
population are used to compare with diseased cases. Useful to find association 
and also rare adverse events. Smaller size of study population is the major 
advantage. The disadvantages are difficulty in selecting cases, controls, 
collecting datas and interpretation of results. 
COHORT STUDIES 
        Cohorts are group of individuals who are identified, characterized and 
followed over time to determine the outcome incidence. Such studies are 
conducted both prospectively and also retrospectively. The advantages are 
predetermined characters, advance information to collect datas, calculation of 
attributable risk. The disadvantages are biases and cost of study.  Rare adverse 
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event are detected very rarely. The following are some examples: Framingham 
Heart study, Physicians and Nurses health study. 
RANDOMIZED CLINICAL TRIALS  
        This is a prospective clinical trial which involves two or more groups to 
assess the effectiveness of drug therapy. Double blinding is done to avoid bias. 
There are some limitations like controlled situations as per ICH GCP 
guidelines, duration, cost and sample size. Some ADRs can be identified at this 
stage. 
DATABASE RESEARCH AND MONITORING 
              The health care records like hospital admissions, out patient’s visits, 
records of pharmacy are made to be recorded and stored in computerized 
database so that it becomes easy to access and evaluate the association between 
the exposure and outcome. The advantages are large number of people 
identified, temporal associations between disease and adverse event, providing 
datas for pharmaco-epidemiological studies, and cost effectiveness. The 
disadvantages are accuracy, needs validation and the possibilities of 
confounding bias. 
META ANALYSIS    
Results of many individual studies are combined and systematic review 
is done. Example for Meta analysis was the study conducted to evaluate the 
association between green tea consumption and the risk of gastric 
cancer.43Some ADRs are analyzed at this level. 
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ADR AND SYSTEMIC MANIFESTATIONS 
           Reportable ADR- “All significant or unusual adverse drug reactions as 
well as unanticipated or novel events that are suspected to be drug related.”44 
Examples are Hypersensitivity reactions, Life –threatening reactions causing 
disability, idiosyncratic reactions secondary to drug interactions.  
Common drugs causing ADRs 
                 ADRs are commonly caused by Antibiotics, Antineoplastics, 
Anticoagulants, Cardiovascular drugs, Hypoglycemics, Antihypertensive, 
NSAID/Analgesics, Diagnostic agents, and CNS drugs. Drugs most involved in 
ADRs causing admissions are Anti-rheumatics and Analgesics (27%), 
Cardiovascular drugs(23%), Psychotropic drugs(14%), Antidiabetics (12%),  
Antibiotics (7%) and Corticosteroids (5%).  
ADR AND SYSTEM ORGAN CLASSIFICATION 
Dermatologic/Allergic, Hematologic, Central Nervous system, 
Peripheral Nervous system, Cardiovascular, Respiratory, Gastrointestinal, 
Renal/genitourinary, Hepatobiliary, Metabolic, Endocrine, Musculoskeletal 
system are various systems affected by adverse drug reactions.  Individual 
system manifestation is explained as follows. 
SKIN AND APPENDAGES DISORDER 
              Dermatitis - Eczema /exfoliative, Eruptions - fixed, lichenoid, 
pustular. Urticaria/angioedema, Erythema multiforme, Steven Johnson 
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syndrome, Toxic epidermal necrolysis, Reactions - photosensitivity, 
phototoxic, photoallergic reactions are caused by Drugs. 
IMMUNOLOGY 
          Anaphylaxis, drug fever, urticaria, angioedema, serum sickness, malaise, 
rigors/shivering, withdrawal syndrome/rebound effects are due to adverse drug 
reactions. 
HEMATOLOGIC SYSTEM 
            Bone Marrow depression / agranulocytosis, hemolysis, cytopenias like 
anemia, granulocytopenia, nuetropenia, thrombotic thrombocytopenic purpura, 
vasculitis, coagulation disorders, thrombosis, embolism, thromboembolism - 
arterial, venous /pulmonary occurs due to  drugs.  
PSYCHIATRY 
             Anorexia, apathy, delirium, depersonalization, depression, personality 
disorder, psychosis, psychotic reaction, thinking abnormalities and thought 
disturbances are caused by drugs as adverse effects. 
CNS/PNS 
                  Sedation - antihistamines, Syncope - chloral hydrate, lithium, 
neuroleptics, quinidine, Dizziness - antidepressants, calcium channel blockers,  
nitrates, Enchelopathy, Convulsions - antibiotic ciprofloxacin, Speech disorder, 
Dysphonia, Hypertonia, Hypotonia, Paralysis, 
Neuropathy - Nitrofurantoin,  gait abnormality, extra pyramidal disorder, 
choreoathetosis, dyskinesia - metachlopramide, oculogyric crisis, 
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anticholinergic syndrome, neuroleptic malignant syndrome and serotonin 
syndrome. 
EYE 
             Cataract, keratitis, retinal disorder and vision abnormalities. 
ENT 
           Ototoxicity 
CARDIOVASCULAR SYSTEM 
              Cardiac failure including shock - beta blockers, circulatory failure, 
hypertension-systemic and pulmonary, hypotension including postural - 
hydralazine, syncope, Mycarditis, cardiomyopathy, angina pectoris, infarction, 
ischemia, coronary artery disorder, thrombosis, endocarditis, mitral 
insufficiency, fibrosis - endocardial, pericarditis,  hemopericardium, pericardial 
effusion, Arrhythmias, AV block, cardiac arrest, fibrillation - atrial/ventricular, 
palpitation and  torsa de pointes are caused by drugs as adverse reactions. 
RESPIRATORY SYSTEM    
                    Adult respiratory distress syndrome, asphyxia, hypoventilation/ 
hypercapnia, hypoxia, dyspnoea,  apnoea,  bradypnoea, asthma / COPD-beta 
blockers, Pneumonitis /alveolitis-Nitrofurantoin, interstitial lung disease, 
pulmonary fibrosis, pulmonary edema and respiratory depression/ arrest are 
caused as adverse reactions to drugs. 
GIT   
Inflammation of esophagus, gastroduodenal region - antibiotics, colon - 
antibiotics, ascites, diarrhea, constipation, dyspepsia - OHAS, upper 
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gastrointestinal bleeding - corticosteroids, pancreatitis-antibiotics, abdominal 
pain, dyspepsia, git infarction/necrosis/gangrene, hematemesis/melena/ 
hematochezia, paralytic ileus, intestinal ischemia, obstruction, perforation, 
stenosis, and peritonitis are adverse reactions to drugs. 
HEPATOBILIARY SYSTEM  
           Cholestatic jaundice, hepatocellular jaundice, mixed, LFT abnormalities, 
Hepatitis - Nitrofurantoin, antidepressants, viral hepatitis like - halothane, 
isoniazid, phenytoin, focal hepatitis - aspirin, chronic hepatitis-methyldopa, 
diclofenac, zonal necrosis-paracetamol and  carbon tetrachloride, cholestasis - 
oral contraceptives, anabolic steroids  and androgens, inflammatory cholestasis 
- allopurinol, co-amoxiclav, carbamazepine, ductal cholestasis - 
chlorpromazine, flucloxacilln, microvesicular steatosis - aspirin, ketoprofen 
and tetracyclines, Macro vesicular changes - acetaminophen, methotrexate, 
phospholipidosis, Granulomas - allopurinol, phenytoin, isoniazid, quinine, 
penicillin, quinidine, venocclusive disease-chemotherapeutic agents, bush tea, 
peliosis hepatis - anabolic steroids, hepatic vein thrombosis - oral 
contraceptives,  Neoplasm - vinyl chloride combined oral contraceptives, 
anabolic steroids arsenic and thorotrast are various adverse effects. 
GENITOURINARY SYSTEM 
              1) Urinary retention-trihexylphenidyl  2) Hematuria - warfarin  
3) Acute kidney injury - ACE I, ARB, NSAID, immunosuppressants  
4) Tubular epithelial damage - ATN-AGs, contrast agents, platins, fovirs, 
immunosuppressants 5) Osmotic nephrosis -  mannitol, ig, dextran  
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6) Tubulointerstistial disease like allergic interstitial nephritis-penicillin, 
ciprofloxacin,  NSAIDs,  PPI, loop diuretics, 7) Nephrocalcinosis - sodium 
phosphate, 8)Papillary necrosis - analgesics, 9) Glomerular nephritis - gold, 
lithium, NSAIDs, vasculitis 10)Thrombosis - hydralazine, propyl thiouracil, 
chelators, allopurinol, pencillamine 11) Obstructive nephropathy ( intratubular) 
- acyclovir, sulfa drugs, indinavir,12)  Nephrolithiais - sulfa drugs, triamterene 
and thrombolytics. 
 
ENDOCRINE SYSTEM 
Amenorrhea, loss of libido, hypoglycemia, hyperglycemia, weight loss 
and weight gain are adverse effects caused by drugs. 
METABOLIC AND NUTRITONAL DISORDERS 
          Fluid and electrolyte disturbances, retention - corticosteroids, 
dehydration - diuretics, hypoglycemia - insulin, oral hypoglycemic agents, 
acidosis and gout are adverse effects of drugs. 
MUSCULOSKELETAL AND COLLAGEN VASCULAR DISORDERS                          
Rhabdomyolysis -  atorvastatin and fluconazole, pathological fracture, 
myopathy, myositis, osteoporosis, LE syndrome, retroperitoneal fibrosis and 
vasculitis are adverse effects caused by drugs. 
            Since the study is related with drug induced skin reactions the detailed 
description of   these reactions follows. 
Drug induced skin reaction 
Cutaneous drug reactions are caused by several different mechanisms  
like immunological or non-immunological  and this was already explained in 
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the mechanism of ADR. The drugs most often responsible for eruptions are 
antimicrobial agents and antipyretic/anti-inflammatory analgesics.45 
Diagnosis  
           The drug reactions cannot be easily distinguished from naturally 
occurring eruptions.  Uncertainty prevails. Drug rash may be similar to rash in 
viral infection. 
When more than one drug is taken then the reaction to one particular 
drug is difficult to establish. Severe reactions affects mucous membrane, causes 
blisters, skin detachment, fever, edema lips and genitals, face, necrosis of skin, 
and breathing difficulties. 
              The useful diagnostic tool is timing of reaction. Reaction occurs 
within a few weeks of drug intake with few exemptions. Knowledge about half 
life of drug is important so that withdrawal is done accordingly. The risk–
benefit potential is considered before discontinuing drugs. 
Treatment 
1) Symptomatic treatment 2) Calamine lotion or systemic antihistamines to 
relieve pruritus  3) topical corticosteroids for local inflammation. 4) Systemic 
corticosteroids-for extensive skin lesions. 
CLASSIFICATION OF DRUG INDUCED CUTANEOUS ERUPTIONS 
MACULOPAPULAR RASH / DRUG RASH 
             Maculopapular rash is the most common type of drug induced skin 
reaction. They manifests as exanthematous lesion like macules which are small, 
distinct, flat areas and papules which are small, raised lesions. The red itchy 
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lesion appears over trunk, extremities and intertriginous areas. Palm and sole 
also affected. 
         Immunohistochemical the mononuclear cellular infiltrate consists mainly 
of CD3+T cells and CD4+T cells in dermis, both CD4 and CD8 cells in 
dermoepidermal junction zone adjacent to basal keratinocyte.46 The drugs that 
causes this type of reaction are  penicillins, sulfonamides, cephalosporins,  
chloramphenicol, gentamicin,  erythromycin, amphotericin, antituberculous 
drugs, nalidixic acid, nitrofurantoin, allopurinol, barbiturates, phenytoin 
thiazides, furosemide, captopril, carbamazepine, gold salts, lithium, 
phenothiazines, phenylbutazone ,quinidine and thiouracil.  
Fixed drug eruption 
            Manifests as erythematous round or oval lesions of a reddish, purple or 
brown colour, with vesicles or bullae. Single lesion appears first. Affects skin 
and mucosa. Frequently affected sites are feet, hand, tongue, external genitalia 
and perianal region. Eruption occurs at the same site along with new lesions 
whenever the causative drug is taken.47 Heals within 7-10 days after stopping 
the drug. Pathogenesis is poorly defined. Genetic susceptibility is seen.48              
             There are many causes like food additives, drugs and pharmaceutical 
excipients. Tetracycline and Co-trimoxazole commonly causes lesions on glans 
penis.49 Oral challenge to confirm the diagnosis is accepted and practised 
safely. Topical corticosteroid reduces the reaction intensity. 
Common drugs causing fixed drug eruptions  are ACE inhibitors, 
allopurinol;  Antimicrobials- penicillin, sulfonamides, tetracyclines, 
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cephalosporins, co-trimaxazole, metronidazole, fluconazole;  Calcium channel 
blockers- amlodipine, diltiazem;  Barbiturates, Benzodiazepines, 
Dextromethorphan, Carbamazepine, Lamotrigine, NSAIDs, Paclitaxel, 
Paracetamol, Phenolphthalein;  Proton pump inhibitors- omeprazole, 
lansoprazole;  and Mercurial diuretics. 
Erythroderma / Exfoliative dermatitis 
             Erythematous rash  with desquamation  occurs as a severe reaction 
pattern due to drug. Systemic symptoms like fever, lymphadenopathy and 
anorexia are also present. Associated complications are hypothermia, fluid and 
electrolyte loss, and infection. Drugs causing such reactions are penicillin, 
sulfonamides, chloroquine, isoniazid and phenytoin. 
Urticaria and Angio-oedema 
      Second most common form of cutaneous drug reaction after maculopapular 
rash. Also known as nettle rash or hives. Urticaria is associated with 
anaphylaxis, angio-oedema or serum sickness. Often becomes more severe 
leading to death. Present as raised, itchy, red blotches or wheals with pale 
centre. Rapid onset in nature occurs within hours of exposure.  
         Utricarial swelling of deep dermal and subcutaneous tissues, mucous 
membranes is called as Angioedema which is a vascular leakage. When 
angioedema affects respiratory tract obstruction, it leads to death.  
        Serum sickness has systemic symptoms like fever and arthralgia. Lips, 
tongue and genitals are affected. Mechanisms involved are immunologic 
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histamine release and non-immunologic histamine release. Ig E, Complement 
activation, release of cutaneous mast cell mediators, and altered chemical 
pathways such as arachidonic acid metabolism plays role in the mechanism. 
Serum sickness like reaction differs from true serum sickness by absence of 
immune complexes, hypocomplementaemia, vasculitis and renal 
involvement.50               . 
                Skin tests like radio allergen absorbent test (RAST), leukocyte, 
histamine release, tryptase measurement help to identify the cause. Positive 
rechallenge confirm the cause.  
Drugs causing urticaria / angioedema with specific mechanism is explained as 
follows: 
1) Drugs acting through IgE receptors: A) Antibiotics-penicillins, 
cephalosporins,  sulfonamides, tetracyclines B) Antiepileptics 
2) Drugs that cause mast cell degranulation: Opioids, codeine, 
tubocurarine, atropine, quinine, hydralazine, vancomycin, radio contrast 
media and pentamidine. 
3) Drugs that pharmacologically promote or exacerbate urticaria 
monoclonal antibodies: Aspirin, NSAIDs and ACE inhibitors. 
4)  Immune complex formation:  Thiouracils, penicillin, sulfonamides. 
5)  Precipitation and activation of complement:   Cholecystographic dyes 
and amino salicylic acid. 
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6)  Excipients in the medication like Benzoic acid, butylated 
hydroxytoluene, sulfites, aspartame, colourings, and preservatives 
provoke allergic or pseudoallergic reactions. 
Acneiform eruptions  
                The drug eruptions resemble acne vulgaris. Papulopustular lesions 
appear without comedones. Drugs causing such reactions are oral 
contraceptives, haloperidol, corticotrophin (ACTH), androgens (in females), 
corticosteroids, isoniazid, phenytoin, iodides and lithium. 
Psoriasiform eruptions 
                   Eruptions are similar to idiopathic psoriasis and consist of 
erythematous plaques covered by large dry silvery scales. Reaction time is less 
than one month to 3 month.  Drugs that cause psoriasiform eruptions or 
exacerbate psoriasis are as follows:  Alfa interferons, beta blockers, lithium, 
ACE inhibitors, NSAIDs, chloroquine,  hydroxychloroquine, terbinafine, 
digoxin, penicillamine, gold, granulocyte colony-stimulating factor (G-CSF), 
tumor necrosis factor and tetracycline. 
Purpura 
           The lesion is small cutaneous extravasations of blood. It is an occasional 
drug-induced skin eruption. Platelet function tests are within normal limits. 
Common drugs causing this type of reaction are aspirin, sulfonamides, quinine, 
penicillin and atropine. 
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 Vasculitis 
                     Inflammation of the blood vessel is called as vasculitis.  
Vasculitides is a diverse group of conditions presents as systemic or cutaneous 
disorder. The mechanism is due to Type III hypersensitivity reaction with 
immune complex deposition in capillaries. Raised purpuric (purple) lesions size 
of about a pin head to few centimeters is seen over leg. Sometimes 
hemorrhagic blisters and ulceration also seen over upper extremities and trunk . 
1) Leukocytoclastic vasculitis is the most common type. For accurate 
diagnosis skin biopsy is needed in which the histopathological features 
of necrosis of cutaneous blood vessel walls with neutrophil infiltration 
are seen.  
2) Another type of vasculitis is Henoch–Schonlein purpura which involves 
other systems like joints, gastrointestinal system, heart, central nervous 
system and kidneys.  Aspirin, penicillins, quinidine, gold are associated 
with this type of vasculitis.  
3) Rare types of vasculitis are polyarteritis nodosa-like vasculitis, pustular 
pigmented purpuric dermatoses and pustular hypersensitivity vasculitis. 
The following drugs causes  cutaneous vasculitis:     Beta-lactam 
antibiotics, Cotrimoxazole, Minocycline, Erythromycin, sulfonamides,  
Allopurinol, Hydralazine, Carbamazepine, NSAIDs, Interferon’s,  
Granulocyte-Macrophage colony stimulating factors, Penicillamine, Diltiazem, 
Propylthiouracil, Retinoids, Gold, Sulfasalzine, Furosemide and Thiazides. 
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Erythema Multiforme, Stevens–Johnson syndrome and Toxic Epidermal 
Necrolysis 
Erythema Multiforme (EM), Stevens–Johnson syndrome (SJS) and 
Toxic Epidermal Necrolysis (TEN) are severe drug induced cutaneous 
reactions. Fever and a flu-like syndrome develop before skin eruption. 
Erythema, blisters, papular lesions affects trunk, hands, feet and limbs. 
Target or iris lesion is the characteristic feature of Erythema Multiforme.  
Mucosa of mouth, eyes and genitalia are affected in Steven Johnson syndrome. 
(SJS) Fever, malaise, arthralgia, myalgia with extensive erythema multiforme 
of face and trunk is seen in SJS. Fatality rate is 5%. 
The reaction mainly involves CD4+ T cells and CD8+ T cells. CD4+ T 
cells predominant in upper dermis while epidermal CD8+ T cells and 
macrophages are variable and Langerhans’s cells virtually disappear.51 
Inducible Nitric acid synthase is demonstrable in skin in SJS/TEN indicating 
the role of nitric oxide in keratinocyte apoptosis and necrosis.52           
Erythema Multiforme or Stevens–Johnson Syndrome are caused by drugs 
like co-trimoxazole, sulfonamides, macrolides, penicillins, cephalosporins, 
barbiturates carbamazepine, phenytoin, lamotrigine, NSAIDs, gold, 
rifampicin,histamine, H2-antagonist, leflunomide, thiazides and 
chlorpropamide. 
Toxic Epidermal Necrolysis 
Lyell’s syndrome or toxic epidermal necrolysis is characterized by 
widespread full-thickness epidermal necrosis involving 30% and more areas of 
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body surface. The mortality is high around 40%. Co morbid conditions like 
HIV infection, systemic lupus erythematosus and bone marrow transplant 
recipients worsen this condition.  Lesion starts on face or upper trunk as 
erythematous macules, irregular target-like bulla or erythema. Massive 
epidermal loss causes dehydration, increased energy expenditure, septicemia 
due infection, organ dysfunction and finally death. The reaction starts with in 
2-8 weeks of drug intake and may progress inspite of discontinuation. 
The drugs causing toxic epidermal necrolysis are antitubercular drugs, 
NSAIDs, carbamazepine, sulfonamides, penicillins, griseofulvin, tetracyclines, 
gold, leflunomides, allopurinol and barbiturates. 
Blistering drug eruption  
                Flaccid blisters along with erythema, scaling are seen in pemphigus. 
Linear IgA deposition along the basement membrane zone is seen. Drug 
induced reaction is manifested as phemphigus like lesion and also similar to 
porphyria cutanea tarda, pemphigoid and linear IgA bullous dermatosis. Drugs 
and types of reaction follow:  
1)  Pemphigus: gold/sodium aurothiomalate, captopril, cephalosporins, 
penicillin, piroxicam   and penicillamine. 
2)  Bullous pemphigoid:   penicillamine, chloroquine, furosemide, ACE 
inhibitors, sulphasalazine and penicillin.   
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3)  IgA bullous dermatosis:   lithium, ceftriaxone, co-trimoxazole, 
furosemide, G-CSF, interleukin-2, captopril, NSAIDs, penicillin, 
rifampicin and vancomycin. 
4)  Pseudoporphyria cutanea tarda:   tetracycline,  NSAIDs, furosemide and  
thiazides. 
Photosensitivity:   
              The reaction occurs to photosensitizing agent which may be topical or 
systemic drug. The reaction may be photo-toxic or photo-allergic and occurs 
within 5-20 hrs of exposure as erythema, blisters and desquamation. This 
reaction forms 8% of cutaneous drug reactions. The drugs associated are 
demeclocycline, sulfonamides, lomefloxacin, amiodarone, antidepressants 
(tricylic, MAOIs), phenothiazines, carbamazepine, quinine, quinidine, 
retinoids, St John’s Wort, sulphonylureas and thiazides. 
Lichenoid drug eruptions 
             The reaction resembles idiopathic lichen planus. Arsenicals used in the 
treatment of syphilis are the first drug that has caused lichenoid reaction. Small 
purplish polygonal papules are seen over trunk and legs. CD4+Tcells capable 
of producing IFN gamma and TNF alpha have been implicated in the 
development of lichenoid drug eruption.53 Drugs that cause this reaction are 
antimalarials, arsenicals, captopril, methyldopa, penicillamine, carbamazepine, 
furosemide, phenytoin, gold, sulfonylureas, proton pump inhibitors and beta 
blockers. 
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Pigmentary disorders 
             Skin colour changes are seen due to drug intake. Localised or 
widespread Pigmentation is seen. Like chloasma, affects the arms, face, neck, 
shins and pretibial areas. Melanin pigmentation is altered. Corneal depositions 
and retinal damage also frequently coexists in some patients. Rarely reaction 
may persist for years. 
               The drugs causing  pigmentation are Mepacrine (yellow), 
Amiodarone (slate grey), Chloroquine (blue-grey or brown), Gold (blue-grey), 
Chlorpromazine (blue-grey), Gold (blue-grey), Phenytoin (brown), 
Minocycline, Cytotoxic agents and Oral contraceptives(brown), rifampicin 
(red) and Methylsergide maleate (red). 
Alopecia 
Alopecia is hair loss caused by many drugs. Daily 100 hairs are shed out 
of 100000 hairs. Three cyclical stages namely anagen, catagen, telogen are 
undergone by hair follicles which lasts for 3 years. Anagen is growing phase. 
Catagen is involutionary phase. Telogen is the resting phase. 
Soft and colourless hairs over   palms and soles are called vellus hairs. 
Over scalp, eyebrows, axillae are large pigmented, coarse hairs called terminal 
hairs. Anagen effluvium is drug induced cessation of anagen growth. Telogen 
effluvium is drug induced hair loss in telogen phase. Hair loss is seen over 
scalp, eyebrows and pubic area.  
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Androgenic alopecia is male pattern baldness seen in women due to 
drugs with androgenic activity like metyrapone, anabolic steroids, danazol and 
estrogen receptor antagonist tamoxifen. 
Drugs causing alopecia are as cyclophosphamide, bleomycin, platinum 
compounds, vinca alkaloids, amphetamines, heparin, warfarin, heparinoids, 
leflunomide, interferons, oral contraceptives, lithium, cimeditine, antithroid 
drugs and cimetidine. 
Excess hair growth 
Excessive growth of coarse hair with masculine features is called as 
Hirsutism. Occurs due to androgenic stimulation of hair follicles by hormones. 
Drugs commonly responsible include testosterone, danazol, corticotrophin, 
anabolic steroids and glucocorticoids.  
The growth of terminal or vellus hair is called as hypertrichosis. 
Hypertrichosis caused by minoxidil is used for male pattern baldness as topical 
application. Hypertrichosis is caused by drugs like nifedipine, penicillamine, 
cyclosporine, phenytoin, diazoxide, methoxalen and verapamil. 
Nail disorders 
Nail changes like horizontal notches (Beau’s line), brittle nails, 
separation of nail plates (onycholysis) and erythema over nail folds 
(paronychia) are caused by drugs. May be due to toxic effect of drug on the 
epithelia of nail and blood vessels of nail bed leading to necrosis. 
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              The drugs causing nail disorders are lithium, chloramphenicol, 
chlorpromazine, pencillamine, gold, thiazides, retinoids, captopril, cytotoxic 
agents, fluroquinolones and tetracyclines. 
Measures to prevent ADR:  
Adverse effects also occur  due to human errors.  The physician should 
ask history of prior allergies and adverse reactions in all patients before 
prescribing drugs. Other history like concomitant medication, OTC, substance 
abuse alternative forms of medications should be enquired. Clarity must be 
there while writing the drug, route, frequency and duration in the case records. 
Short hand forms and abbreviations are not to be used by physicians. After 
giving instructions to the patient feedback should be obtained. No drugs should 
be given over phone.           
Adverse drug reactions are preventable in most of the cases if provoking 
factors are identified as early as possible. Early intervention is must to avoid 
mortality. 
This study is designed to bring about the findings which may help to 
minimize the impact due to ADRs. 
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AIM AND OBJECTIVES OF THE STUDY 
     To study the profile of different clinical manifestations of drug induced 
skin reactions in the patients attending outpatient department of Dermatology 
in a tertiary care hospital. 
Primary objective 
 To analyze different groups of drugs causing drug induced skin 
reactions. 
Secondary objective 
1. To describe the Causality analysis of drug induced skin reactions by 
using WHO causality assessment scale54  and Naranjo’s algorithm.55  
2. To describe the severity analysis of drug induced skin reactions by using 
Hartwig and Seigel scale.56  
3. To describe the nature of different types of skin reactions. 
4. To describe socio-demographic profile in drug induced skin reactions. 
5. To investigate the role of gender in causing drug induced skin reactions. 
6. To analyze the predisposing factors. 
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MATERIALS AND METHODS 
Study Design:         Descriptive study. 
Study Period:         September 2011 to February 2013 
Study centre:         Dermatology Out-patient Department, Government 
Kilpauk Medical College, Chennai-10. 
Study population: Patients with drug induced skin reactions attending Out-
patient Department of Dermatology. 
Sample Size:          All patients with drug induced skin reactions who attend 
the OPD of dermatology 
Inclusion criteria 
1. Patients of all ages, belonging to both genders presenting to 
Dermatology Out-patient clinic with skin reactions following intake of 
any drug. 
2. Patients referred from other clinical specialties to Dermatology OPD for 
the treatment of drug induced reactions. 
Exclusion Criteria 
1. Patients with other skin conditions. 
2. Patients not willing to consent for participation in the study. 
Ethical consideration 
The study was approved by the Institutional Ethics Committee. 
Confidentiality and anonymity of the patients  information were 
maintained during and after the study. 
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Treatment and care of the patient was not interfered during the study 
process. 
Study Procedure 
             All the patients with drug induced skin reaction attending the 
Dermatology outpatient department were registered after obtaining informed 
consent. Patients with other skin reactions were excluded. All the details 
regarding patient’s basic data, present illness, past medical history, co-
morbidities, concomitant medications, and family history were collected and 
recorded in the proforma. Details of the drugs suspected to be causing ADR 
and the details of cutaneous lesions were recorded in the proforma. A detailed 
clinical history and physical examination was done. The prescription details 
available with the patient were also collected. The clinical diagnosis of drug 
induced skin reaction was confirmed by the dermatologist.  
The data was recorded in the Suspected Adverse Drug Reaction 
Reporting Form  obtained from Central Standard Control Organisation.57 The 
patient’s initials but not the names were recorded to maintain the privacy and 
confidentiality. Basic data like age, gender, height, weight were recorded. 
.Details of cutaneous reaction like date of start and recovery, type of cutaneous 
ADR. were recorded. Details of suspected drug causing ADR, and details of 
concomitant medications were recorded.  The relevant medical history and 
details of applicable test in relation to cutaneous reaction were recorded. The 
data were analyzed and causality assessment of ADR was done by using WHO 
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causality assessment scale58 and Naranjo Algorithm.55 Severity of ADR was 
assessed by Modified Hartwig and Siegel Assessment Scale.56 
Statistical Analysis 
Data collected were categorically charted on a Windows Microsoft 2007 
system. The data was analyzed using SPSS software, Stat graphics plus and 
Excel. Diagrams and graphs were used to make relevant comparisons. 
Statistical significance was analyzed by using Chi- Square Test. 
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RESULTS 
The details of 100 cases were recorded.  All details recorded as per 
“CDSCO suspected adverse drug reporting forms” were analyzed. The data 
was analyzed using suitable statistical packages. Various statistical significant 
tests were used to find the parametric significance and inferences were derived. 
The details are described below. 
Patients’ demographic details like age and gender analysis were done. 
AGE: 
The age wise distribution of ADRs in different age groups is shown below: 
  
Table 1:  Age wise distribution 
  
 
Age  in years Frequency Percent 
<= 30 33 33.0 
31-40 25 25.0 
41-50 23 23.0 
51-60 13 13.0 
> 60 6 6.0 
Total 100 100.0 
 
 33% of drug induced skin reaction was common in the age group years <30 
years. 6% of ADR was seen above 60 years. 
Figure 1: Age wise distribution
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GENDER:  
 
Table 2:   Gender distribution of patients with ADRs 
  
 
        Gender Frequency Percent
 Male 54 54.0 
  Female 46 46.0 
  Total 100 100.0 
 
. 
Drug induced skin reaction was found more in males compared to females. 
 
 
Figure 2:    Gender distribution of patients with ADRs 
 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
5446
Male
Female
 51
ONSET OF DRUG REACTION 
 
 
Table 3:  Time interval between drug intake and onset of drug reaction  
 
 
Time of onset Number of cases 
1st   day 13 
2nd    day 23 
3rd  day 18 
4th day 7 
5th day 8 
6-14th day 16 
15th -21st day 5 
22nd -28th day 2 
28th -35th day 3 
36th -42nd day 3 
43rd -49th day 1 
50th -56th day 1 
 
 
         On the day of drug intake 13 cases were affected by drug induced skin 
reaction. More number of cases was seen after 24 hours. 
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ADVERSE REACTION – PROFILE OF DRUG INDUCED SKIN 
REACTION  
 
Table 4:      Frequency of different types of Drug induced skin reactions 
  
 
 
 
Most common drug induced skin reactions was Drug Rash (44%). 
Figure 3: Frequency of different types of Drug induced- skin reaction 
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Drug reaction Frequency Percent 
Drug Rash 44 44.0 
Erythema multiforme 14 14.0 
Toxic epidermal necrolysis 4 4.0 
Steven-Johnson syndrome 2 2.0 
Fixed drug eruption 18 18.0 
Urticaria 6 6.0 
Urticarial vasculitis 7 7.0 
Drug induced purpura 4 4.0 
Drug induced Photo 
dermatitis 1 1.0 
Total 100 100.0 
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SUSPECTED DRUGS 
 
Table 5:    Frequency of various groups of   drugs suspected to be the causative 
agents 
 
                 Suspected drugs Frequency Percent
Antiepileptics 6 6.0
NSAIDs 24 24.0
Muscle relaxant 1 1.0
Antibacterial agents 32 32.0
Antileprotic drugs 3 3.0
Antiretroviral drugs 15 15.0
Antimalarial drugs 2 2.0
Antifungal 1 1.0
OHAs 2 2.0
Antihypertensive 1 1.0
Antiulcer agents 1 1.0
Antimetabolite 2 2.0
Vaccine 1 1.0
Unknown 4 4.0
Fixed drug combination 4 4.0
Hypolipaedemic drugs 1 1.0
Total 100 100.0
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Figure 4:     Frequency of various groups of   drugs suspected to be the 
causative agent
 
Antibacterial agents are most commonly causing drug induced skin reaction 
followed by NSAIDs.   
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CONCOMITANT MEDICATIONS 
Table 6:       Pattern of use of Concomitant Medications 
 
 Concomitant 
medications Frequency Percent 
 Yes 85 85.0 
  No 15 15.0 
  Total 100 100.0 
 
 
Concomitant medications were used in 85% of Cases. 
 
 
Figure 5:  Pattern of use of  Concomitant Medications 
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SERIOUSNESS OF REACTION 
  
 Table 7:      Distribution of Seriousness of reaction 
 
  
 
 Seriousness of reaction Frequency Percent 
 1) Required Intervention to 
prevent permanent damage 87 87.0
  2)Life threatening  9 9.0
  3) Requiring Hospitalization 4 4.0
  Total 100 100.0
 
 87 % of cases required intervention to prevent permanent damage, and 9% of 
cases were life threatening required intensive monitoring. 
 
Figure 6: Distribution of Seriousness of reaction 
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OUTCOME 
 
Table 8:  Distribution of outcome 
 
  
        Outcome Frequency Percent 
 Recovered 37 37.0 
  Recovering 62 62.0 
  Death 1 1.0 
  Total 100 100.0 
 
 One case died, 37 cases recovered and 62 cases were in recovery phase 
regarding outcome. 
 
Figure 7: Distribution of outcome 
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CAUSALITY ASSESSMENT OF ADR 
 
Table 9:  Causality Assessment of ADRs by WHO Scale 
 
  
 
 Causality 
assessment Frequency Percent
 Certain 4 4.0
  Possible 44 44.0
  Probable 52 52.0
  Total 100 100.0
 
Maximum ADRs were Probable (52%). 44 ADRs were Possible and 
only 4 ADRs were Certain.    
   Figure 8: Causality Assessment of ADRs by WHO Scale 
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 CAUSALITY ASSESSMENT OF ADR: 
 
Table 10: Causality assessment ADRs by Naranjo Algorithm 
 
 
Causality assessment Frequency 
Possible 0 
Probable 100 
Definite 0 
 
 
By Using Naranjo Algorithm all ADRs were Probable with score of 6-7. 
 
 
ADR SEVERITY ASSESSMENT SCALE: 
 
 
Table 11:  ADR severity assessment by using Modified Hartwig and Siegel 
Scale-1992 
 
 Level 1  Level 2 Level 3 Level 4 Level 5 Level 6 Level 7 
Number 
of ADRs 
0 0 87 4 8 0 1 
 
 
87 % of ADRs were moderately severe requiring discontinuation of the 
suspected drug and was amenable to management with medications as 
outpatient. 
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Age versus seriousness of reaction 
 
Table 12:     Distribution of Age versus seriousness of reaction 
  
 
  Seriousness of Reaction Total 
Age in years 
Required 
Intervention 
to prevent 
permanent 
damage 
Life 
threatening
Requiring 
Hospitalization  
 1. <= 30 27 4 2 33 
 2. 31-40 23 1 1 25 
 3. 41-50 20 2 1 23 
 4. 51-60 11 2 0 13 
 5. > 60 6 0 0 6 
            Total 87 9 4 100 
 
 
 
Chi-Square Tests 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-
Square 3.599(a) 8 .891
Likelihood Ratio 4.890 8 .769
Linear-by-Linear 
Association .994 1 .319
N of Valid Cases 100   
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Figure 9: Distribution of Age versus seriousness of reaction 
 
 
 
 
  
All ADRs required intervention in all age groups.  
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AGE VERSUS OUTCOME OF ADRs: 
 
 
Table 13:  Distribution of outcome of ADRs in different Age Groups 
 
 
    
Outcome Total 
Recovered Recovering Death 
Age 
Group in 
years 
<= 30 Count 13 19 1 33
% within 
Age Group 
in years 
39.4% 57.6% 3.0% 100.0%
% within 
Outcome 35.1% 30.6% 100.0% 33.0%
31-40 Count 11 14 0 25
% within 
Age Group 
in years 
44.0% 56.0% .0% 100.0%
% within 
Outcome 29.7% 22.6% .0% 25.0%
41-50 Count 7 16 0 23
% within 
Age Group 
in years 
30.4% 69.6% .0% 100.0%
% within 
Outcome 18.9% 25.8% .0% 23.0%
51-60 Count 5 8 0 13
% within 
Age Group 
in years 
38.5% 61.5% .0% 100.0%
% within 
Outcome 13.5% 12.9% .0% 13.0%
> 60 Count 1 5 0 6
% within 
Age Group 
in years 
16.7% 83.3% .0% 100.0%
% within 
Outcome 2.7% 8.1% .0% 6.0%
Total Count 37 62 1 100
% within 
Age Group 
in years 
37.0% 62.0% 1.0% 100.0%
% within 
Outcome 100.0% 100.0% 100.0% 100.0%
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Chi-Square Tests 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-
Square 4.261(a) 8 .833 
Likelihood Ratio 4.576 8 .802 
Linear-by-Linear 
Association .472 1 .492 
N of Valid Cases 100    
 
 
Figure 10:    Distribution of outcome of ADRs in different Age Groups 
 
 
 
 
 
 
All age groups patient were mostly in the recovery phase. No statistical 
significant difference between age and outcome as the P value= .833. 
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GENDER VERSUS SERIOUSNESS OF REACTION 
 
Table 14:    Distribution of Gender versus Seriousness of Reaction  
  
  
 
  
  
  
  
Seriousness of Reaction 
Total Required Intervention 
to prevent 
permanenet 
damage 
Life 
threatening 
Requiring 
Hospitali-
zation 
Sex Male Count 48 4 2 54
    % within 
Sex 88.9% 7.4% 3.7% 
100.0
%
    % within 
Seriousness 
of Reaction 
55.2% 44.4% 50.0% 54.0%
  Female Count 39 5 2 46
    % within 
Sex 84.8% 10.9% 4.3% 
100.0
%
    % within 
Seriousness 
of Reaction 
44.8% 55.6% 50.0% 46.0%
Total Count 87 9 4 100
  % within 
Sex 87.0% 9.0% 4.0% 
100.0
%
  % within 
Seriousness 
of Reaction 
100.0% 100.0% 100.0% 100.0%
 
Chi-Square Tests 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-
Square .405(a) 2 .817
Likelihood Ratio .403 2 .817
Linear-by-Linear 
Association .251 1 .616
N of Valid Cases 100   
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Figure 11:    Distribution of Gender versus Seriousness of Reaction 
 
 
 
 
 
  
 
              The seriousness of reaction was mostly similar in both sexes. There is 
no significant difference between sex and seriousness of reaction as the p 
value=.817 found by using Chi-square test. 
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GENDER VERSUS OUTCOME 
 
Table 15:  Distribution of Gender versus Outcome 
 
  
 
    Outcome Total 
    Recovered Recovering Death   
Sex Male Count 19 34 1 54
    % within Sex 35.2% 63.0% 1.9% 100.0%
    % within 
Outcome 51.4% 54.8% 100.0% 54.0%
  Female Count 18 28 0 46
    % within Sex 39.1% 60.9% .0% 100.0%
    % within 
Outcome 48.6% 45.2% .0% 46.0%
Total Count 37 62 1 100
  % within Sex 37.0% 62.0% 1.0% 100.0%
  % within 
Outcome 100.0% 100.0% 100.0% 100.0%
 
Chi-Square Tests 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-
Square .974(a) 2 .614
Likelihood Ratio 1.354 2 .508
Linear-by-Linear 
Association .330 1 .566
N of Valid Cases 100   
 
 
 
. 
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Figure 12: Distribution of Gender versus Outcome 
 
 
 
 
One male patient died due to ADR .There is no statistical difference between 
sex and outcome. By using Chi-square test the p value = .614 which is not 
significant statistically. 
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Concomitant medications versus seriousness of reaction 
 
Table 16:  Distribution of Concomitant Medications versus Seriousness of 
Reaction 
Concomitant Medications 
  
  
Seriousness of Reaction Total 
Required 
Intervention 
to prevent 
permanent 
damage 
Life 
threatening 
Requiring 
Hospitali
zation 
  
 Yes Count 72 9 4 85
    % within 
Concomitant 
Medications 
84.7% 10.6% 4.7% 100.0%
    % within 
Seriousness of 
Reaction 
82.8% 100.0% 100.0% 85.0%
  No Count 15 0 0 15
    % within 
Concomitant 
Medications 
100.0% .0% .0% 100.0%
    % within 
Seriousness of 
Reaction 
17.2% .0% .0% 15.0%
Total Count 87 9 4 100
  % within 
Concomitant 
Medications 
87.0% 9.0% 4.0% 100.0%
  % within 
Seriousness of 
Reaction 
100.0% 100.0% 100.0% 100.0%
 
Chi-Square Tests 
 
 Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-
Square 2.637(a) 2 .268
Likelihood Ratio 4.555 2 .103
Linear-by-Linear 
Association 2.284 1 .131
N of Valid Cases 100   
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Figure 13:    Distribution of Concomitant Medications versus Seriousness of 
Reaction 
 
 
  
 
 
The seriousness of reaction (85%) was found to be more when concomitant 
medications were used. There is no statistical significant difference between 
seriousness of reaction and concomitant medications used as the p value =.268 
found by using Chi-square test. 
 
 
 
 
 
 
 
Concomittant Medications
NoYes
C
ou
nt
80
60
40
20
0
Seriousness of React
Required Interventio
n to prevent permane
Life threatening
Requiring Hospitaliz
ation
 70
DRUG REACTION VERSUS OUTCOME 
  
Table 17:       Distribution of Drug Reaction versus Outcome 
 
  
 Outcome Total 
Drug Reaction Recovered Recovering Death  
Drug Rash 13 31 0 44
Erythema multiforme 7 7 0 14
Toxic epidermal necrolysis 1 2 1 4
Steven-johnson syndrome 1 1 0 2
Fixed drug eruption 4 14 0 18
Urticaria 6 0 0 6
Urticarial vasculitis 4 3 0 7
Drug induced purpura 1 3 0 4
Drug induced Photodermatitis 0 1 0 1
Total 37 62 1 100
 
 
Chi-Square Tests 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-
Square 
40.509(
a) 16 .001
Likelihood Ratio 25.021 16 .069
Linear-by-Linear 
Association 1.027 1 .311
N of Valid Cases 100   
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Figure 14:       Distribution of Drug Reaction versus Outcome 
 
 
 
 
 Fatality (1%) was seen among patients with toxic epidermal necrolysis 
(4%) whereas all types of skin reactions were mostly in recovering phase. 
There is no statistical significance between type of reaction and outcome of 
ADR. 
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Drug reaction versus Age group 
 
Table 18:  Distribution of   different types of drug reaction versus  Age  group 
 
  Age Group in years Total 
 Type of drug reaction     <= 30 31-40 41-50 51-60 > 60   
  Drug Rash 19 12 11 2 0 44
  Erythema multiforme 5 1 5 2 1 14
  Toxic epidermal 
necrolysis 3 1 0 0 0 4
  Stevenjohnson 
syndrome 0 0 0 2 0 2
  Fixed drug eruption 5 5 3 1 4 18
  Urticaria 0 4 1 1 0 6
  Urticarial vasculitis 1 0 2 3 1 7
  Drug induced purpura 0 1 1 2 0 4
  Drug induced 
Photodermatitis 0 1 0 0 0 1
Total 33 25 23 13 6 100
 
Chi-Square Tests 
 
  Value df
Asymp. 
Sig. (2-
sided)
Pearson Chi-
Square 
59.482(a
) 32 .002
Likelihood Ratio 56.722 32 .005
Linear-by-Linear 
Association 11.705 1 .001
N of Valid Cases 100   
 
Drug rash was most common in the age group of < 30 years (19%). 
Steven-Johnson syndrome (2%) was seen only in the age group 51-60 years. 
There is statistical significance between age and drug reaction as the p value 
=.002 by Chi-Square test. 
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Figure 15:     Distribution of different types of drug reaction versus Age group 
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DIFFERENT TYPES OF DRUG INDUCED SKIN REACTION VERSUS 
GENDER 
 
Table 19:     Distribution of different types of drug reaction versus gender 
 
  
 
  Sex Total 
   Type of drug reaction        Male Female   
 Drug Rash 20 24 44 
  Erythema 
multiforme 7 7 14 
   
  Toxic epidermal 
necrolysis 1 3 4 
  Steven-johnson 
syndrome 1 1 2 
   
  Fixed drug 
eruption 13 5 18 
  Urticaria 5 1 6 
  Urticarial 
vasculitis 4 3 7 
  Drug induced 
purpura 3 1 4 
  Drug induced 
Photodermatitis 0 1 1 
             Total 54 46 100 
 
Chi-Square Tests 
 
  Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-
Square 9.147(a) 8 .330
Likelihood Ratio 9.940 8 .269
Linear-by-Linear 
Association 3.313 1 .069
N of Valid Cases 100   
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Figure 16 : Distribution of different types of  drug reaction  versus gender  
 
 
 
Drug rash was most common in females (54.5%) than males (45.5%). 
Steven Johnson Syndrome and Erythema Multiforme has equal distribution. 
Other reactions were distributed more in Males. There was no statistical 
difference between sex and drug reaction. The p value =.330 is not statistically 
significant found by using Chi-Square test. 
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SUSPECTED DRUG VERSUS AGE GROUP 
 
Table 20: Distribution of Suspected Drug causing reaction versus Age Group in 
years 
  Age Group in years Total 
Suspected Drug <= 30 31-40 41-50 51-60 > 60   
  Antiepileptics 3 0 1 1 1 6
  NSAIDs 8 7 4 4 1 24
  Muscle relaxant 0 0 1 0 0 1
  Antibacterial agents 9 9 7 4 3 32
  Antileprotic drugs 2 1 0 0 0 3
  Antiretroviral drugs 4 6 4 1 0 15
  Antimalarial drugs 0 0 1 1 0 2
  Antifungal 0 0 1 0 0 1
  OHAs 0 1 1 0 0 2
  Antihypertensive 0 0 0 1 0 1
  Antiulcer agents 0 0 1 0 0 1
  Antimetabolite 0 0 1 1 0 2
  Vaccine 1 0 0 0 0 1
  Unknown 3 0 1 0 0 4
  Fixed drug 
combination 3 0 0 0 1 4
  Hypolipaedemic 
drugs 0 1 0 0 0 1
Total 33 25 23 13 6 100
 
Chi-Square Tests 
 
  Value df
Asymp. 
Sig. (2-
sided)
Pearson Chi-
Square 
53.512(a
) 60 .710
Likelihood Ratio 55.661 60 .635
Linear-by-Linear 
Association .421 1 .517
N of Valid Cases 100   
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Figure 17:  Distribution of Suspected Drug causing reaction versus Age Group 
in years 
 
 
 
 There is no significant difference between suspected drug causing 
reaction and age.  
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SUSPECTED DRUG VERSUS GENDER 
 
Table 21:          Association of Suspected Drug versus Gender 
 
 
                     Suspected drug Sex Total 
  Male Female   
 Antiepileptics 1 5 6
  NSAIDs 11 13 24
  Muscle relaxant 1 0 1
  Antibacterial agents 19 13 32
  Antileprotic drugs 1 2 3
  Antiretroviral drugs 6 9 15
  Antimalarial drugs 2 0 2
  Antifungal 1 0 1
  OHAs 2 0 2
  Antihypertensive 1 0 1
  Antiulcer agents 1 0 1
  Antimetabolite 0 2 2
  Vaccine 0 1 1
  Unknown 3 1 4
  Fixed drug 
combination 4 0 4
  Hypolipaedemic drugs 1 0 1
Total 54 46 100
                                  
Chi-Square Tests 
 
  Value df
Asymp. Sig. 
(2-sided)
Pearson Chi-
Square 21.389(a) 15 .125
Likelihood Ratio 27.740 15 .023
Linear-by-Linear 
Association 4.340 1 .037
N of Valid Cases 100   
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Figure 18:        Association of Suspected Drug versus Gender 
 
 
 
 Females were affected more by Antiepileptics (5), NSAIDs (13), Antiretroviral 
drugs (9) and Antimetabolite (2).  Antibacterial (19), Fixed drug combinations 
(4%), have affected more males. There is no significant difference between 
drug groups and sex as the p value = .125. 
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DISCUSSION 
AGE 
            Table 1 and Figure 1 show that 33% of drug induced- skin reaction was 
common in the age group < 30 years.  25 % of ADRs were seen in 31-40 years 
followed by 23 % in 41-50 years and 13 % in 51-60 years. About 6 % of ADR 
was seen above 60 years. Hence the age group more commonly affected was < 
30 years.     
Sushma et al in their study found that drug induced skin reactions were 
mostly seen in third and fourth decades of life.59 In our study more reaction 
were seen in the age group< 30 years. Hence more caution should be taken 
while prescribing medicines to this age group. 
GENDER 
Table 2 and Figure 2 show that Drug induced- skin reactions were found 
more in males (54%) compared to females (46%).However it is not statistically 
significant. But both genders are vulnerable.       
Mahmood Farshchian et al studied 308 patients with adverse cutaneous 
drug reaction from 2007–2009 and   found that  Females (63%) were more 
commonly affected  than males (37%).60 In our study males (54%) were more 
affected than females(46%) but statistically not significant. 
ONSET OF REACTION 
Table 3 shows the time interval between the drug intake and onset of 
adverse reaction. On the day of drug intake 13% were affected by drug induced 
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skin reactions. More number of cases was affected after 24 hours. The 
inference from this was that in sensitized patients the reactions starts earlier. 
The frequency of cases decreased as the time progresses but still the reaction 
has occurred. Even after 4 weeks interval the drug reactions occurred and was 
caused by antiretroviral drugs. Hence physician should be alert  upto three 
weeks.  
 ADVERSE DRUG REACTION 
Table 4 and Figure 3 show the profile of drug induced -skin reactions. 
Most common drug induced skin reactions was Drug Rash (44%) followed by 
Fixed drug eruption (18%) and Erythema Multiforme (14 %).  Less than 10 % 
lesions were Toxic epidermal necrolysis (4%), Steven Johnson Syndrome 
(2%), Utricaria (6%) and Urticarial Vasculitis (7%). Less than 5% lesions were 
Drug induced purpura (4%) and Drug induced Photo dermatitis (1%). 
Mahmood Farshchian et al studied 308 patients with adverse cutaneous drug 
reaction from 2007–2009 and found that  Acute urticaria was the most common 
clinical presentation (59.2%) followed by fixed drug eruptions (18.5%), and 
maculopapular eruptions (14.9%).60 
           Noel, et al found that drug rash was the common the most common type 
of cutaneous drug reaction.6 Study performed by Souissi et al in 2007, found 
that the most common cutaneous clinical manifestation was maculopapular 
eruption followed by fixed drug eruptions, and antibiotics and NSAIDs were 
the most commonly causing agents.63 Results of this study were comparably 
similar to the studies of Noel and Souissi et al. 
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 Table 17 and Figure 14 show the distribution of drug reactions versus 
their outcomes. Out of 4 cases of toxic epidermal necrolysis  one patient died. 
All other types of skin reactions were mostly in recovering phase. There is no 
statistical significance between type of reaction and outcome. 
Table 18 and figure 15 shows the distribution of different types of drug 
reactions   versus age group. Drug rash was most common in the age group of 
< 30 years (19%).  Steven Johnson Syndrome (2%) was seen only in the age 
group 51-60 years. Exact mechanism for this is not known. There is statistical 
significance between age and drug reaction as the p value =.002 by Chi-Square 
test. 
Study of 464 case series reported by Kauppinen K   found that 4% 
patients had Steven Johnson Syndrome.64 In our study 2% of patients had 
Steven Johnson Syndrome. 
           Table 19 and Figure 16 show the distribution pattern of different type of 
drug reactions versus genders. Drug rash was more common in females 
(54.5%) than males (45.5%). Steven Johnson Syndrome and erythema 
multiforme have equal distribution between both genders. Other reactions were 
distributed more in males. However there was no statistical difference between 
sex and type of drug induced skin reaction. The p value =.330 is not 
statistically significant found by using Chi-Square test. 
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SUSPECTED DRUG 
           Table 5 and Figure 4 show the frequency of various group of drugs 
suspected to be the causative agents. Antibacterial agents (32%) were the most 
common agents causing drug induced skin reaction followed by NSAIDs 
(24%) and antiretroviral agents (15%).  4 % of drug eruptions were caused by 
fixed drug combinations. 4 % of lesions were caused by unknown drugs were 
the patient was unable give details about the drug taken. Muscle relaxant, 
Antifungal, Antihypertensive, Antiulcer, and Vaccine has caused 1 % of 
reaction individually. 
          Mahmood Farshchian et al studied 308 patients with adverse cutaneous 
drug reaction from 2007–2009 and found  that Beta-lactam antibiotics was 
found to be the most frequent cause of adverse cutaneous drug reactions 
(42.7%), followed by non-steroidal anti-inflammatory drugs (16.5%).60 
        Ghosh, et al in Manipal found that Antimicrobials were the most common 
group causing cutaneous drug reaction.61  In our study also  antibacterial agents  
have caused more drug induced skin reactions which was comparably similar 
to the above studies.                 
           Table 20 and figure 17 show the distribution of suspected drug causing 
reaction versus age group. Antiepileptics (3), NSAIDs (8), Antibacterial agents 
(9) Antileprotics (2), Vaccine (1) caused drug reactions more in the age group 
< 30 years. Antimetabolites and Antimalarials caused reaction in the age group 
51-60 years and > 60 years. There is no significant difference between 
suspected drug causing reaction and age. By using Chi-square test the  
p value=.710 which is not statistically significant. 
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          Table 21 and Figure 18 show the association of suspected drug versus 
gender.  Females were affected more by Antiepileptics (5), NSAIDs (13), 
Antiretroviral drugs (9) and Antimetabolite (2). Other groups of drugs like 
Antibacterial (19), Fixed drug combinations (4%), have affected more males 
compared to females. There is no significant difference between drug groups 
and gender. The p value = .125 assessed by Chi-Square test is not statistically 
significant. 
           Suspected drugs that caused drug reaction were 1) Antibacterial agents - 
Amoxicillin, Ampicillin, Co-trimaxazole, Doxycycline, Tetracycline, 
Ciprofloxacin, Levofloxacin, Ofloxacin, Cefixime, Vancomycin.  
2) Antitubercular drug - Pyrazinamide, 3) Antileprotic drug - Dapsone  
4) Antifungal – Griseofulvin 5) Antiretroviral drugs - Nevirapine and Efavirenz 
6) Antimalarial - Artesunate, Primaquine 6) NSAIDs – Diclofenac, 
Aceclofenac, Nimuselide, Prophiphenazone and Piroxicam. 7) Muscle relaxant 
- Thiocolchicoside, 8) Antiepileptics - Carbamazepine, and Phenytoin.   
9) H2 blocker - Ranitidine 10) Oral hypoglycemic agent - Glibenclamide and 
Metformin. 11) Antihypertensive - Atenolol, 12) Antimetabolite - Methotrexate 
13) Vaccine - Antirabies vaccine, 14) Hypolipidaemic drug- Rosuvastatin. 
        Oral route (96%) was the most common route of drug administration 
whereas parenteral route of administration was found only in 4% of cases. All 
drugs were given in appropriate doses except in cases where the drug history 
was not known. 
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CONCOMITTANT MEDICATIONS AND CO-MORBIDITIES 
           Table 6 and Figure 5 show that Concomitant medications were used in 
85% of Cases. The medications were used for co-morbidities like hypertension, 
hypothyroidism, diabetes mellitus, AIDS, seizure disorder, bronchial asthma, 
cardiac disorders, postpartum sepsis, brain tuberculoma, post surgical sepsis, 
tuberculosis, leprosy, systemic lupus erythematosus, burns, and prostate 
enlargement. Hence polypharmacy may have increased the incidence of ADRs. 
An Australian study done by Stanton et al showed that 4.4% of all 
adverse drug reactions resulting in hospital admission were due to drug 
interactions.27  In our study since concomitant medications were also used drug 
interaction could also have played a role in causing drug reaction. This has to 
be researched in future. 
LAB DETAILS 
Laboratory investigations pertaining to the ADR- Drug induced purpura 
was done to rule out hematological disorders and also for severe reactions.  
Laboratory investigations were also done for co-morbidities.   
SERIOUSNESS OF REACTION 
Table 7 and Figure 6 show the seriousness of adverse drug reactions. All 
cases required interventions in the form of stopping the drug, symptomatic 
management and hospitalization for severe reactions. 87 % of cases required 
intervention to prevent permanent damage and were managed without 
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hospitalization. 4% of cases were hospitalized in the dermatology ward for 
management. 9% of cases were life threatening required intensive care 
monitoring.  
              Table 12 and Figure 9 Shows that the all ADRs required intervention 
in all age  groups.  
Table 14 and figure 11 show that the seriousness of reaction was mostly 
similar in both sexes. There is no significant difference between sex and 
seriousness of reaction as the p value=.817 found by using Chi square test. 
Table 16 and figure 13 show the distribution of concomitant medications 
and seriousness of reaction. The seriousness of reaction (85%) was found to be 
more when concomitant medications were used. There is no statistical 
significant difference between seriousness of reaction and concomitant 
medications used as the p value =.268 found by using Chi-Square test. 
OUTCOME 
          Table 8 and Figure 7 show the outcome of drug induced skin reaction.  
37 cases recovered.  62 cases were in recovery phase as per the CDSCO 
Suspected adverse drug reaction form report. One case died due to severe life 
threatening serious drug reaction. History of drug allergy was present in that 
case which could have been prevented. 
       Table 13 and Figure 10 show that maximum numbers of patients were 
recovering in all ages. The patient who died due to severe ADR belongs to the 
age group < 30 years. 
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            Table 14 and figure 11 show that the seriousness of reaction was mostly 
similar in both genders. The admission rate was similar in both genders 
(Female -7% and Male- 6). There is no Significant difference between gender 
and seriousness of reaction as the p value = .817 found by using Chi square 
test. 
              Table 15 and figure 12 show the distribution of Gender versus 
Outcome. One male Patient died due to ADR .There is no statistical difference 
between gender and outcome. By using Chi-square Test the p value = .614 
which is not significant statistically. 
CAUSALITY ASSESSMENT 
         Table 9 and Figure 8 show the Causality Assessment by using WHO 
causality assessment Scale. 52 ADRs were Probable, 44 ADRs were Possible 
and only 4 reactions were Certain.  
      Sachin Hiware et al study shows the causality assessment by WHO 
causality assessment scale for 872 CDRs. The period of study was from june 
2005 to may 2009. It was found to have 580 certain, 260 probable and 32 
possible CDRs.65 In our study 100 ADRs were analyzed and the Causality 
assessment of  ADR done  by WHO assessment scale revealed that 52 ADRs 
were Probable, 44 ADRs were Possible and  4 ADRs were  Certain.  
Only 4 ADRs were certain as rechallenge was not done. 
           Table 10 shows the Causality assessment by using Naranjo algorithm. 
All ADRs were Probable with score of 6-7. 96 % of ADRs score was 6 and  
4% of cases had previous history of drug allergy and the score was 7. 
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SEVERITY ASSESSMENT OF ADR 
           Severity assessment of ADR was done by using Modified Hartwig and 
Siegel Scale - 1992.   Table 11 shows that 87 % of ADRs were moderate in 
severity. 9% of patients were hospitalized for severe ADR. Out of which  
1 patient died due to severe Toxic epidermal necrolysis. 
LIMITATIONS OF THE STUDY  
            The study was done in a limited group of population. The concentration 
of drug in blood or other samples was not detected which may be helpful in 
preventing the toxic dose concentration.  Rechallenge for drug reaction was not 
performed in the study due to ethical consideration. 
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CONCLUSION 
The study was undertaken to analyze the profile of drug induced skin 
reaction in Outpatient department of Dermatology and to assess the causality, 
severity and socio-demographic profile of adverse drug reaction. The sample 
size analyzed was 100. The aim and objectives were met. Most common age 
group affected belongs to < 30 years. Men (56%) were more affected. Drug 
rash was the most common drug induced reaction. The suspected drug causing 
more number of reactions was antibacterial agents. 52 ADRs were probable,  
44 ADRs were possible and 4 reactions were certain. Wi 
thdrawal of drug along with symptomatic management has made 
complete reversal of drug reactions to normality except one drug reaction-
Toxic epidermal necrolysis due to the suspected drug group NSAID which 
terminated fatally. Hence the study gives a representative view about the ADRs 
among patients attending dermatology O.P in a tertiary care hospital. 
India is the fourth largest manufacturer of pharmaceutical products in 
the world and emerging as clinical trial hub. Hence constant vigilance in 
detecting ADRs is needed so that drug therapy is safe and effective. Possible 
preventive measures to reduce ADRs are 1) to avoid inappropriate use of drugs, 
2) to use appropriate dose, route and frequency of drug administration based on 
patients variables, 3) previous history of drug reaction should be considered 
and 4)  appropriate laboratory monitoring. 15-20 % of hospital budget is spent 
for the treatment of ADR.66 Hence ADR database studies are  conducted across 
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multiple centres through active collaboration with various specialists and 
pharmacologists which can provide early warning signals of drug reaction and  
widens  Pharmacovigilance in India.  
            Hippocrates admonition “atleast no harm” should be followed by all 
Health care professionals. 
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ANNEXURE A 
PATIENT DATA COLLECTION – PROFORMA 
DEPARTMENT OF PHARMACOLOGY, KMC , CHENNAI. 
1. DATE    : 
2. OP NO   : 
3. NAME    : 
4. AGE (yrs)    : 
5. GENDER    : 
6. HEIGHT(cm)   : 
7. WEIGHT(kg)   : 
8. ADDRESS   : 
9. OCCUPATION   : 
10. CONTACT NUMBER : 
 
 
 
 
Complaints: 
 
 
 
History of present illness: 
 
 
 
Past history: 
 
 
Personal history: 
 
 
Family history: 
 
 
Clinical Examination: 
 
 
 
 
 
 
Investigations: 
 
 
 
 
Diagnosis: 
 
 
 
         

                                                   ANNEXURE - B 
INFORMED CONSENT FORM 
Title of the study : Study of drug induced-skin reactions among patients 
attending outpatients department of dermatology.  
Name of the participant :    Age    Sex : 
IP No: 
Name of the Principal investigator :  
Name of the Institution : Department of Pharmacology, Kilpauk Medical 
College, Chennai – 600 010.  
Documents of the informed consent  
I____________________ have read the information in this form (or it has been 
read to me). I was free to ask any questions and they have been answered. I am   
exercising my free power of choice, hereby give my consent to be included as a 
participant in “Study of drug induced-skin reactions among patients attending 
outpatients department of dermatology” 
1. I have read and understood this consent form and the information 
provided to me.  
2. I have had the consent document explained to me 
3. I have been explained about the nature of the study.  
4. I have been explained about my rights and responsibilities by the 
investigator. 
5. I have been informed the investigator of all the treatments I am taking or 
have taken in the past including any native (alternative) Treatment. 
6. I agree to cooperate with the investigator and I will inform her 
immediately if I suffer unusual symptoms.  
7. I have not participated in any research study in the past  
8. I am aware of the fact that I can opt out of the study at any time without 
having to given any reason and this will not affect my future treatment in 
this hospital.  
9. I am also aware that the investigator may terminate my participation in 
the study at any time, for any reason, without my consent.  
10. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the  regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly 
presented.  
11. I have understood that my identity will be kept confidential if my data 
are publicly  presented.  
12. I have had my questions answered to my satisfaction. 
13. I have decided to be in the research study.  
14. I am aware that if I have any question during this study, I should contact 
the investigator. By signing this consent form I attest that the information 
given in this document has been clearly explained to me and understood 
by me, I will be given a copy of this consent document.  
Signature & Date    
 
 
 
 
 
 
 
 
 
 
               

APPENDIX-C 
WHO CAUSALITY ASSESSMENT SCALE FOR 
SUSPECTED ADVERSE DRUG REACTIONS 
(The Uppsala monitoring centre 2002) 
Term Description  
Certain  Event or laboratory test abnormality, with plausible time 
relationship to drug intake 
 Cannot be explained by disease or other drugs 
 Response to withdrawal plausible(pharmacologically, 
pathologically) 
 Event definitive pharmacologically or phenomenological(i.e. 
an objective and specific medical disorder or a recognized 
pharmacological phenomenon) 
 Rechallenge satisfactory, if necessary  
Probable/Likely  Event or laboratory test abnormality, with reasonable  time 
relationship to drug intake 
 Unlikely  to be attributed to disease or other drugs  
 Response to withdrawal clinically reasonable 
 Rechallenge not required  
 
Possible  Event or laboratory test abnormality ,with reasonable  time 
relationship to drug intake 
 Could not be explained by the disease or other drugs  
 Information on drug withdrawal may be lacking or unclear  
 
Unlikely  Event or Laboratory test abnormality with a time to drug 
intake that makes a relationship improbable(but not 
impossible) 
 Disease or other drugs provide plausible explanations 
 
Conditional/ 
Unclassified 
 Event or Laboratory abnormality 
 More data for proper assessment needed, or  
 Additional data under examination 
Unassessable / 
Unclassifiable 
 Report suggesting an adverse reaction  
 Cannot be judged because information is insufficient or 
contradictory 
 Data cannot be supplemented or verified 
APPENDIX –D 
CRITERIA FOR DETERMINING CAUSATIVE DRUG RELATIONSHIP TO  
ADVERSE DRUG REACTION (NARANJO ALGORITHM-1981) 
The total score calculated from this table defines this category as: Possibly (Total Score 1-4) , 
Probably (Total Score 5-8) , Definitely (Total Score > 9) 
Questions Yes No Do Not 
Know 
Score 
Are there previous conclusive 
reports on this reaction? 
+1 0 0  
Did the adverse event appear after 
the suspected drug was given? 
+2 -1 0  
Did the adverse reaction improve 
when the drug was discontinued or 
a specific antagonist was given? 
+1 0 0  
Did the adverse reaction appear 
when the drug was Re-
administered? 
+2 -1 0  
Are there alternative causes (other 
than the drug ) that could have 
caused the reaction? 
-1 +2 0  
Did the reaction reappear when a 
placebo was given? 
-1 +2 0  
Was the drug detected in blood (or 
other  body fluid) in toxic 
concentrations? 
+1 0 0  
Was the reaction more severe 
when the dose was increased or 
less severe when the dose was 
decreased? 
+1 0 0  
Did the patient have a similar 
reaction to the same or similar 
drugs in any previous exposure? 
+1 0 0  
Was the event confirmed by 
objective evidence? 
+1 0 0  
                          Total score     
                                                       APPENDIX - E 
                                 ADR SEVERITY ASSESSMENT SCALE 
 
Modified Hartwig and Siegel scale-1992 
 
 
MILD 
Level 1:  An ADR occurred but required no change in treatment with the suspected drug. 
Level 2:  The ADR required that treatment with the suspected drug be held, discontinued, or 
otherwise changed. No antidote or other treatment requirement was required. No increase in 
length of stay. 
MODERATE 
Level 3:   The ADR required that treatment with the suspected drug be held, discontinued, or 
otherwise changed, and / or  an antidote or other treatment was required. No increase in length of 
stay. 
Level 4:  Any level 3 ADR which increases length of stay by at least 1 day or the ADR was the 
reason for the admission. 
SEVERE 
Level 5:  Any level 4 ADR which requires intensive medical care. 
Level 6:  The ADR caused permanent harm to the patient. 
Level 7:  The ADR either directly or indirectly led to the death of the patient.  
 
 
               FILE PICTURES OF DRUG INDUCED SKIN REACTIONS 
 
Picture 1: Drug induced urticaria 
 
  
Picture2&3: Drug induced rash 
 
 Picture4: Bullous FDE 
 
 
Picture 6: Bullous FDE with erosion 
 
 
Picture5: FDE 
 
 
Picture 7: Multiple FDE 
 
Fixed Drug Eruption (FDE)
TOXIC EPIDERMAL NECROLYSIS (TEN)
 
 
 
 
 
 
 
 
Picture 8 
Picture 9: TEN 
with peeling
Picture10 &11: TEN with mucosal 
 Picture12: Erythema multiforme 
with target lesions 
 
 
 
 
  
Picture13: Erythema multiforme 
with target lesions 
 
 
 
Picture14: Steven Johnsons syndrome 
  
 
Picture 16: Urticarial vasculitis 
 
  
 
 Picture17 & 18: Photosensitive drug eruptions 
Picture15: Steven Johnson syndrome with p
